Details of the Drug

General Information of Drug (ID: DMS104F)

• Drug Name: Temsirolimus
• Synonyms: Torisel

Indication

Disease Entry	ICD 11	Status	REF
Renal cell carcinoma	2C90	Approved	[1]

• Affected Organisms: Humans and other mammals
• ATC Code:
  L01EG01: Temsirolimus
  L01EG: Mammalian target of rapamycin (mTOR) kinase inhibitors
  L01E: PROTEIN KINASE INHIBITORS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 4:
  Molecular Weight (mw); 1030.3
  Logarithm of the Partition Coefficient (xlogp); 5.6
  Rotatable Bond Count (rotbonds); 11
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 16
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
  Clearance: The clearance of drug is 16.2 L/h []
  Elimination: 4.6% of drug is excreted from urine in the unchanged form [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 17.3 hours (temsirolimus), and 54.6 hours (sirolimus) [3]
  Metabolism: The drug is metabolized via the cytochrome P450 3A4 in the human liver []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.14767 micromolar/kg/day [4]
  Vd: The volume of distribution (Vd) of drug is 172 L []
  Water Solubility: The ability of drug to dissolve in water is measured as 0.01 mg/mL [2]
• Chemical Identifiers:
  Formula: C56H87NO16
  IUPAC Name: [(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
  Canonical SMILES: C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC
  InChI: InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1
  InChIKey: CBPNZQVSJQDFBE-FUXHJELOSA-N
• Cross-matching ID:
  PubChem CID: 6918289
  ChEBI ID: CHEBI:79699
  CAS Number: 162635-04-3
  UNII: 624KN6GM2T
  DrugBank ID: DB06287
  TTD ID: D0ES1Q
  VARIDT ID: DR00432
  INTEDE ID: DR1548
  ACDINA ID: D01471

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[5]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[7]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[7]

Molecular Expression Atlas of This Drug

• The Studied Disease: Renal cell carcinoma
• ICD Disease Classification: 2C90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serine/threonine-protein kinase mTOR (mTOR)	DTT	MTOR	2.16E-05	-0.44	-2.3
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.04E-02	-1.13E+00	-1.00E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	3.51E-02	1.53E+00	1.16E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	5.84E-01	-1.61E-01	-3.61E-01

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1; GDSC2	-0.86	18.2375	-9.845	38.2004
ES8	GDSC1; GDSC2	-5.5722	13.3511	-11.7428	51.159
EW-7	GDSC1; GDSC2	-2.9302	11.1693	-8.1817	41.8194
HOS	GDSC1; GDSC2	-2.0347	8.529	-6.0597	35.5307
ES7	GDSC1; GDSC2	-1.9703	16.2079	-9.7993	40.7634
SK-PN-DW	GDSC1; GDSC2	-1.3324	14.68	-8.4779	37.6395
EW-13	GDSC1; GDSC2	-1.2508	16.6141	-9.3712	38.5644
ES5	GDSC1; GDSC2	-0.9209	24.5035	-13.0274	41.0828
ES4	GDSC1; GDSC2	-0.8926	13.4226	-7.469	34.8898
ES1	GDSC1; GDSC2	-0.5803	18.7316	-9.8537	37.59
EW-16	GDSC1; GDSC2	-0.5578	19.8123	-10.3748	38.1234
EW-11	GDSC1; GDSC2	-0.5416	24.3002	-12.6043	40.09
EW-12	GDSC2	-0.2042	8.8627	-4.6026	26.0234
TC-71	GDSC1; GDSC2	0.0131	13.9042	-6.9412	31.4799
SK-ES-1	GDSC1; GDSC2	0.0567	2.7419	-1.324	7.9325
CHSA0108	GDSC1; GDSC2	0.0757	10.5071	-5.1906	26.6372
G-292 clone A141B1	GDSC1; GDSC2	0.4154	12.3358	-5.8253	27.6552
EW-3	GDSC1; GDSC2	0.5682	16.4542	-7.7585	31.8249
EW-22	GDSC1; GDSC2	0.5692	14.8454	-6.9539	30.1399
CHSA0011	GDSC1; GDSC2	0.583	12.0568	-5.5497	26.4122
EW-18	GDSC1; GDSC2	0.7083	12.9568	-5.898	27.1189
EW-1	GDSC1; GDSC2	0.7253	12.4953	-5.654	26.3654
EW-24	GDSC1; GDSC2	0.811	10.0148	-4.3486	21.641
MG-63	GDSC1; GDSC2	0.8374	25.5001	-12.059	37.1593
HuO-3N1	GDSC1; GDSC2	1.0163	21.0451	-9.6881	34.0577
NOS-1 [Human HNSCC]	GDSC1; GDSC2	1.1839	15.8939	-6.9831	28.7783
HuO9	GDSC1; GDSC2	1.2172	19.9058	-8.9576	32.55
MHH-ES-1	GDSC1; GDSC2; CTRP2	1.3346	24.8964	-7.5461	42.332
A-673	GDSC1; GDSC2	1.3937	14.6864	-6.2165	26.3672
CADO-ES1	GDSC1; GDSC2; CTRP2	2.0782	6.645	1.5382	25.958
U2OS	GDSC1; GDSC2; CTRP2	2.2499	19.1558	-3.8911	37.2125
U-CH2	GDSC2	2.2863	12.2536	-4.3416	18.5533
ES6	GDSC1; GDSC2	2.35	23.0829	-9.6462	31.483
H-EMC-SS	GDSC1; GDSC2	2.357	19.8849	-8.0529	28.6413
CAL-72	GDSC1; GDSC2	2.36	23.8264	-10.0081	32.0131
NY	GDSC1; GDSC2	2.8631	13.7985	-4.6833	18.226
CHSA8926	GDSC1; GDSC2	3.1799	17.8855	-6.451	23.2564
CAL-78	GDSC1; GDSC2; CTRP2	3.5948	17.2039	-1.6885	30.6472
SaOS-2	GDSC1; GDSC2	3.7568	13.627	-3.9946	13.812
SJSA-1	GDSC1; GDSC2; CTRP2	4.79	41.6145	-12.7965	39.9991
SW1353	CTRP2	13.9334	43.8138	-6.738	24.8501

Cancer Drug Sensitivity Data Curated from 194 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	0.9016	50.6248	-20.6644	47.4162
JM1	GDSC1; GDSC2	2.047	5.1023	-1.1149	2.781
KMS-34	CTRP2	-13.3953	1.9073	-14.2013	83.0487
Ramos.2G6.4C10	GDSC1; GDSC2	-12.6417	1.5474	-14.2479	75.1309
Ri-1	CTRP2	-11.8159	18.6008	-17.8867	67.502
L-363	GDSC1; GDSC2; CTRP2	-11.1011	25.3188	-20.0022	62.9534
KMS-26	CTRP2	-10.2439	0.5042	-10.5822	82.5375
CRO-AP2	GDSC1; GDSC2	-10.0144	7.9546	-13.7954	63.9922
SU-DHL-5	GDSC1; GDSC2	-9.8032	-0.9387	-10.4576	73.6126
MLMA	GDSC1; GDSC2	-9.6536	160.3564	-88.3585	51.4506
OCI-Ly7	GDSC1; GDSC2	-9.1537	-0.9257	-9.753	71.7735
SU-DHL-6	GDSC1; GDSC2; CTRP2	-8.5293	10.0815	-11.1208	66.8817
WSU-DLCL2	GDSC1; GDSC2; CTRP2	-8.3022	9.5791	-10.7027	66.8539
Ki-JK	CTRP2	-8.2511	8.9081	-10.4232	69.2386
SR	GDSC1; GDSC2; CTRP2	-8.1916	22.3072	-15.6965	60.4449
YT	GDSC1; GDSC2	-8.0552	2.5036	-9.5825	63.4505
Farage	GDSC1; GDSC2	-7.8973	8.1128	-11.6627	58.9221
MOLT-16	GDSC1; GDSC2; CTRP2	-7.5844	14.6212	-11.8109	62.5225
KMS-21-BM	CTRP2	-7.4903	12.1112	-10.735	65.4719
MHH-PREB-1	GDSC1; GDSC2	-7.2203	27.4741	-20.137	53.2274
SUP-B8	GDSC1; GDSC2	-7.2009	0.5561	-8.0172	62.1185
KE-97	CTRP2	-7.0491	37.9163	-21.7872	56.7111
JVM-3	GDSC1; GDSC2; CTRP2	-6.9941	7.0193	-8.4626	66.2548
SU-DHL-8	GDSC2; CTRP2	-6.9006	37.3029	-21.3513	56.0304
WSU-NHL	GDSC1	-6.6792	1.384	-8.427	52.2173
Karpas-231	GDSC1; GDSC2	-6.5741	-0.0272	-7.1671	59.4834
RPMI-8866	GDSC1; GDSC2	-6.5041	11.6249	-11.84	53.9342
697	GDSC1; GDSC2	-6.2631	10.7195	-11.1809	53.4329
Karpas-422	GDSC1; GDSC2	-6.1858	91.9537	-51.2283	50.573
JeKo-1	GDSC1; GDSC2	-5.9195	7.0531	-9.1687	53.0183
BL-41	GDSC1; GDSC2	-5.8211	0.6803	-6.5508	54.483
RL	GDSC1; GDSC2	-5.7438	4.4507	-7.8659	52.8493
SU-DHL-16	GDSC1; GDSC2	-5.6439	-0.0106	-6.1565	53.5718
MOLT-4	GDSC1; GDSC2	-5.3785	3.4745	-7.0824	51.191
MOLP-8	GDSC1; GDSC2	-5.2635	8.8519	-9.3239	50.379
NU-DUL-1	GDSC1; GDSC2; CTRP2	-5.2538	14.7995	-9.4284	57.9403
KE-37	GDSC1; GDSC2; CTRP2	-5.0793	8.1904	-6.7425	60.4636
CTB-1	GDSC1; GDSC2	-4.9894	21.2187	-15.0086	49.646
MV4-11	GDSC1; GDSC2; CTRP2	-4.8343	10.5413	-7.3006	58.5876
MY-M12	GDSC1; GDSC2	-4.6989	25.2097	-16.7071	49.1614
QIMR-WIL	GDSC1; GDSC2	-4.5263	4.6585	-6.6882	46.6274
A3/Kawakami	GDSC1; GDSC2	-4.2555	2.3958	-5.4634	43.9502
SUP-HD1	GDSC1; GDSC2	-4.2319	15.2471	-11.3848	47.4536
GR-ST	GDSC1; GDSC2	-4.0312	40.1591	-23.5306	48.6037
Jiyoye	GDSC1; GDSC2	-3.6013	6.4824	-6.5771	42.3534
HT	GDSC1; GDSC2; CTRP2	-3.5743	8.1903	-5.1083	55.6246
NCI-H929	GDSC1; GDSC2; CTRP2	-3.5732	18.3712	-9.239	53.3974
SIG-M5	GDSC2	-3.5194	57.4664	-31.7163	48.686
Karpas-299	GDSC1; GDSC2; CTRP2	-3.3836	17.8861	-8.8294	53.0326
L-540	GDSC1; GDSC2; CTRP2	-3.062	36.2689	-17.1961	51.2672
HC-1	GDSC1; GDSC2	-2.7135	6.7129	-5.8192	37.4818
ST486	GDSC1	-2.7053	7.5237	-7.5677	32.427
OPM-2	GDSC1; GDSC2	-2.642	5.1926	-5.0293	35.2685
MHH-CALL-2	GDSC1	-2.6103	3.87	-5.6614	24.7962
Mono-Mac-1	CTRP2	-2.3167	9.9225	-4.3703	53.3456
KMS-12-BM	GDSC1; GDSC2; CTRP2	-2.249	16.591	-7.0976	50.299
EoL-1	GDSC1; GDSC2	-2.1169	14.5647	-9.1139	40.4591
L-1236	GDSC1; GDSC2	-2.0924	6.1381	-4.9493	32.8632
MOLM-13	GDSC1; GDSC2; CTRP2	-1.9715	10.3937	-4.1828	49.365
RC-K8	GDSC1	-1.9131	5.4865	-5.8909	23.3706
KMS-11	GDSC1; GDSC2; CTRP2	-1.9085	28.5844	-12.3863	49.5968
RPMI-6666	GDSC1; GDSC2	-1.8743	11.6864	-7.4704	37.6575
A4/Fukuda	GDSC1; GDSC2	-1.7478	13.6013	-8.307	38.5116
MM1.S	GDSC1; GDSC2; CTRP2	-1.596	18.7653	-7.4306	48.6242
BV-173	GDSC1; GDSC2; CTRP2	-1.5805	30.781	-13.138	49.0762
L-428	GDSC1; GDSC2	-1.5409	5.7557	-4.2449	28.4139
JVM-2	GDSC1; GDSC2; CTRP2	-1.4395	29.3285	-12.301	48.7862
VAL	GDSC1; GDSC2	-1.406	19.057	-10.7242	40.2923
DG-75	GDSC1; GDSC2	-1.223	12.6833	-7.3876	35.6461
BC-1	GDSC1; GDSC2	-1.1874	2.6043	-2.388	18.2272
Sc-1	GDSC1	-1.0757	3.1894	-4.1208	10.0526
KG-1	GDSC1; GDSC2	-1.0254	34.4207	-18.0721	43.679
KMS-28BM	CTRP2	-1.021	12.1243	-3.8848	48.3712
RCH-ACV	GDSC1; GDSC2; CTRP2	-0.9665	34.4663	-14.362	48.2214
U-698-M	GDSC1; GDSC2	-0.8999	21.557	-11.5373	39.93
DB	GDSC1; GDSC2	-0.8907	74.9537	-38.2216	46.9169
Karpas-1106P	GDSC1; GDSC2	-0.8194	52.1529	-26.7624	45.527
SUP-T11	CTRP2	-0.8035	11.5736	-3.4264	47.4516
DoHH2	GDSC1; GDSC2; CTRP2	-0.7948	116.1687	-54.816	49.3701
SUP-M2	GDSC1; GDSC2	-0.7797	7.7185	-4.5269	26.889
PF-382	GDSC1; GDSC2; CTRP2	-0.682	22.3207	-8.2069	46.6927
SUP-B15	GDSC1; GDSC2	-0.5806	17.8042	-9.3904	37.0267
HH [Human lymphoma]	GDSC1; GDSC2	-0.4976	55.4752	-28.1534	45.4516
KOPN-8	GDSC1; GDSC2	-0.4708	27.2031	-13.9959	40.919
GA-10	GDSC1; GDSC2	-0.462	182.5646	-91.6675	48.5905
U266B1	GDSC1; GDSC2	-0.4442	18.0048	-9.3752	36.7
PL-21	GDSC1; GDSC2	-0.436	9.7168	-5.2264	28.2096
Namalwa	GDSC1; GDSC2	-0.3655	7.9148	-4.266	24.6084
BE-13	GDSC1; GDSC2	-0.3579	42.8078	-21.7029	43.9523
CTV-1	GDSC1; GDSC2	-0.2544	14.4782	-7.4521	33.2042
P32/ISH	GDSC1; GDSC2	-0.1827	8.8438	-4.575	25.2444
IM-9	GDSC1; GDSC2	-0.1262	2.0941	-1.154	7.4163
Kasumi-1	GDSC1; GDSC2	-0.1243	15.7058	-7.9567	33.8123
EM-2	GDSC1; GDSC2; CTRP2	-0.0626	13.5228	-3.5045	42.6938
ARH-77	GDSC1; GDSC2	-0.0292	3.1788	-1.6138	9.9347
SU-DHL-4	GDSC1; GDSC2; CTRP2	-0.0277	17.9373	-5.4951	44.0608
EB2	GDSC1; GDSC2	-0.0008	2.6927	-1.347	8.2331
HAL-01	GDSC1; GDSC2	0.0023	14.0386	-7.0174	31.6724
BONNA-12	GDSC2	0.0908	14.9589	-7.4039	32.7637
JJN-3	GDSC1; GDSC2	0.1019	15.4279	-7.6292	32.6686
Jurkat	GDSC1; GDSC2; CTRP2	0.1235	16.8199	-4.8238	43.2398
MN-60	GDSC1; GDSC2	0.1358	17.7033	-8.7387	34.4994
EHEB	GDSC1; CTRP2	0.2171	35.0389	-13.5557	46.3703
BALL-1	GDSC1; GDSC2	0.2289	15.7161	-7.6681	32.4402
WIL2 NS	GDSC1; GDSC2	0.2395	11.7902	-5.6967	27.7454
MEG-01	GDSC1; GDSC2	0.3315	10.2222	-4.8375	24.7424
CESS	GDSC1; GDSC2	0.3519	8.4177	-3.9193	21.0967
CA46	GDSC1; GDSC2	0.3743	11.172	-5.2773	26.1067
ATN-1	GDSC1; GDSC2	0.3984	10.0029	-4.6735	23.9713
P30/OHK	GDSC1; GDSC2	0.4193	7.4072	-3.3603	18.3587
ALL-SIL	GDSC1; GDSC2	0.4488	10.7791	-5.0202	25.0599
JSC-1	GDSC1; GDSC2	0.4497	12.3508	-5.8048	27.5081
NKM-1	GDSC1; GDSC2	0.4652	31.2014	-15.2147	40.1852
RPMI-8226	GDSC1; GDSC2; CTRP2	0.5298	36.3354	-13.911	45.9983
SCC-3	GDSC2	0.5335	23.733	-11.4249	37.4458
Hs 445	GDSC2	0.5533	2.9611	-1.0486	5.1925
NK-92MI	GDSC2	0.5852	3.6075	-1.3423	6.9348
Loucy	GDSC1; GDSC2	0.6081	11.5139	-5.2584	25.4326
CMK	GDSC1	0.6177	9.3497	-5.927	16.3128
CCRF-CEM	GDSC1; GDSC2	0.6229	40.0417	-19.5042	42.0625
NCO2	CTRP2	0.6597	18.4921	-5.0872	43.9255
KHM-1B	CTRP2	0.6876	20.0883	-5.8226	44.2825
H9	GDSC1; GDSC2	0.7031	15.7767	-7.3103	30.6062
JURL-MK1	GDSC1; GDSC2; CTRP2	0.7157	28.7499	-10.0064	44.6114
CML-T1	GDSC1; GDSC2; CTRP2	0.8342	20.9624	-6.1031	42.4411
BC-3	GDSC2	0.86	3.6795	-1.1818	5.3179
KMS-18	CTRP2	0.9547	19.6762	-5.3692	43.375
Karpas-45	GDSC1; GDSC2	1.0863	12.5814	-5.4099	24.7178
THP-1	GDSC1; GDSC2; CTRP2	1.2466	6.3314	0.7273	30.8952
LC4-1	GDSC1; GDSC2	1.3545	12.5641	-5.192	23.359
Peer	CTRP2	1.3993	20.8544	-5.5157	42.4312
VL51	GDSC1; GDSC2	1.4036	13.2281	-5.4838	24.1918
TALL-1 [Human adult T-ALL]	GDSC2; CTRP2	1.4211	10.0437	-0.4617	34.1464
OCI-AML-5	GDSC1; GDSC2	1.4391	7.382	-2.5713	11.772
Granta-519	GDSC1; GDSC2	1.517	8.2847	-2.9562	13.5988
MOLM-16	GDSC1; GDSC2	1.579	14.9382	-6.1975	25.8942
OCI-M1	GDSC1; GDSC2	1.8384	9.1659	-3.1559	13.8695
EJM	GDSC1; GDSC2	2.0402	14.6241	-5.6892	23.3879
KMOE-2	GDSC1; GDSC2	2.075	13.0075	-4.8659	20.5677
Daudi	GDSC1; GDSC2	2.12	11.3201	-4.0052	17.108
TK [Human B-cell lymphoma]	GDSC1; GDSC2	2.2189	13.1532	-4.8315	20.127
LP-1	GDSC1; GDSC2	2.256	4.0801	-0.6024	0.5143
TUR	GDSC1; GDSC2	2.2585	3.8438	-0.5157	0.299
OCI-AML-3	GDSC1; GDSC2	2.2888	21.085	-8.7011	30.0112
PL21	CTRP2	2.3088	22.6324	-5.5369	40.4489
ALL-PO	GDSC1; GDSC2	2.3256	8.0173	-2.2759	8.3882
ROS-50	GDSC1; GDSC2	2.3503	14.6265	-5.4589	21.9912
NALM-6	GDSC1; GDSC2; CTRP2	2.3756	17.7283	-3.0794	35.828
HL-60	GDSC1; GDSC2	2.429	17.3605	-6.7484	25.5327
OCI-Ly19	GDSC1; GDSC2	2.4454	12.9252	-4.5553	18.6118
ML-2	GDSC1; GDSC2	2.4627	16.8628	-6.4774	24.7551
KY821	GDSC1; GDSC2	2.5676	10.6704	-3.3768	13.3815
DND-41	GDSC1; GDSC2	2.6712	12.2568	-4.0703	16.2098
DEL	GDSC1; GDSC2; CTRP2	2.7047	5.4168	2.5498	20.8939
Mono-Mac-6	GDSC1; GDSC2; CTRP2	2.9687	28.3674	-7.7736	39.5434
KMS-27	CTRP2	3.0789	22.9824	-5.0073	38.3481
MC116	GDSC1; GDSC2; CTRP2	3.201	15.274	-1.1114	30.3199
U-937	CTRP2	3.416	8.0744	2.4476	21.0607
SUP-T1	GDSC1; GDSC2; CTRP2	3.4907	19.2599	-2.796	32.914
HDLM-2	GDSC1; GDSC2; CTRP2	3.5677	24.2867	-5.2149	36.1063
K-562	GDSC1; GDSC2	3.7246	13.8129	-4.1036	14.3134
HPB-ALL	CTRP2	3.7561	11.9197	1.0345	25.1417
ME1	GDSC1; GDSC2	3.7577	13.7044	-4.0306	13.9572
Ku812	GDSC1; GDSC2; CTRP2	4.4263	23.4942	-4.0631	33.0261
KM-H2	GDSC1; GDSC2; CTRP2	4.6126	22.9289	-3.6189	32.0139
MOLP-2	CTRP2	4.6303	31.4047	-7.8326	38.109
P12-Ichikawa	GDSC1; CTRP2	4.67	17.8107	-1.02	26.9043
SU-DHL-1	GDSC2; CTRP2	4.9777	8.7702	3.7152	11.3096
P31/FUJ	GDSC1; GDSC2; CTRP2	5.1397	25.8804	-4.6373	32.5638
Reh	GDSC1; GDSC2; CTRP2	5.1613	23.6821	-3.5208	30.8541
MOLT-13	GDSC1; GDSC2; CTRP2	5.3336	34.6179	-8.8389	36.7237
MOLM-6	CTRP2	5.5668	31.4474	-7.0573	35.9453
NOMO-1	GDSC1; GDSC2; CTRP2	5.6232	38.212	-10.3917	37.5024
GDM-1	GDSC1; GDSC2; CTRP2	5.6813	13.8156	1.8522	16.5175
P3HR-1	CTRP2	5.747	28.7188	-5.5415	34.024
Karpas-620	GDSC1; GDSC2; CTRP2	5.7958	21.0869	-1.685	26.2389
REC-1	CTRP2	5.9183	9.7558	4.0826	8.4902
SU-DHL-10	GDSC2; CTRP2	6.0386	16.3293	0.8971	19.3517
SKM-1	GDSC1; GDSC2; CTRP2	6.284	9.6794	4.4225	5.8409
RS4;11	GDSC1; GDSC2; CTRP2	6.696	29.1897	-4.9898	30.5332
RPMI-8402	GDSC1; GDSC2; CTRP2	6.7083	22.3317	-1.5528	24.343
OCI-AML-2	GDSC1; GDSC2; CTRP2	6.8541	25.6211	-3.0776	27.2025
Raji	GDSC1; GDSC2; CTRP2	7.161	25.4507	-2.7446	26.0832
SK-MM-2	GDSC1; GDSC2; CTRP2	7.5626	10.0977	5.0994	1.6753
HEL	GDSC1; GDSC2; CTRP2	7.8909	8.9232	5.7142	0.0558
KCL-22	GDSC1; GDSC2; CTRP2	7.9758	31.0461	-4.8856	28.4901
KMM-1	CTRP2	8.0308	13.7952	3.6732	6.695
MHH-CALL-3	CTRP2	8.1302	28.6178	-3.5546	27.286
KYO-1	CTRP2	9.3264	31.0871	-3.858	26.0405
MHH-CALL-4	GDSC2; CTRP2	10.1599	32.8886	-4.1213	24.5724
AMO1	GDSC1; GDSC2; CTRP2	10.9093	36.5649	-5.3756	25.3961
ME1	CTRP2	11.436	32.5578	-3.032	21.6735
NB4	GDSC1; GDSC2; CTRP2	11.6481	27.3246	-0.3662	14.4156
LAMA-84	GDSC1; GDSC2; CTRP2	14.2177	36.2072	-2.8904	17.3264

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE8	CTRP2	5.4874	21.3986	-2.1017	29.1841
OE21	GDSC1; GDSC2	-0.442	35.8353	-18.2873	42.959
TE-11	GDSC1; GDSC2	0.007	9.2178	-4.603	24.7996
T.T	GDSC1; GDSC2	0.0227	13.3534	-6.6578	30.8156
KYSE-150	GDSC1; GDSC2	0.2399	8.7644	-4.1839	22.5166
KYSE-450	GDSC1; GDSC2	0.567	12.2244	-5.6464	26.7443
KYSE-410	GDSC1; GDSC2; CTRP2	0.7128	39.0978	-15.1117	46.0008
TE-15	GDSC1; GDSC2	0.843	4.965	-1.8198	8.9218
EC-GI-10	GDSC1; GDSC2	1.3345	15.5027	-6.6692	27.6825
OE19	GDSC1; GDSC2	1.3892	11.9232	-4.8471	22.0795
KYSE-520	GDSC1; GDSC2	1.4125	23.2291	-10.4594	34.3438
KYSE-270	GDSC1; GDSC2	1.6781	9.7718	-3.5677	16.1782
TE-5	GDSC1; GDSC2	1.7739	24.3798	-10.7449	34.0573
OE33	GDSC1; GDSC2	1.8527	18.354	-7.6824	28.8851
TE-8	GDSC1; GDSC2	2.1592	14.4061	-5.4923	22.5105
KYSE-510	GDSC1; GDSC2	2.209	8.0263	-2.3553	9.0239
TE-6	GDSC1; GDSC2; CTRP2	2.8116	36.9492	-12.1783	42.2745
COLO 680N	GDSC1; GDSC2; CTRP2	6.3833	17.7158	0.4887	19.6133
KYSE-70	GDSC1; GDSC2; CTRP2	7.3183	25.7894	-2.7876	25.9163
TE-9	GDSC1; GDSC2; CTRP2	7.6206	9.226	5.4969	0.4886
TE-10	GDSC1; GDSC2; CTRP2	8.0905	30.6567	-4.6009	27.8926
TE-4	GDSC1; GDSC2; CTRP2	8.7246	26.3412	-1.9661	22.0948
KYSE-140	GDSC1; GDSC2; CTRP2	10.6131	43.6191	-9.0845	30.3731
KYSE-180	GDSC1; GDSC2; CTRP2	11.8212	27.6704	-0.4162	14.3437
TE-1	GDSC1; GDSC2; CTRP2	13.1614	39.8185	-5.3419	22.7892

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYAE-1	GDSC1; GDSC2	-1.5823	14.4589	-8.587	38.4359
SK-GT-4	GDSC1; GDSC2	0.1116	33.8668	-16.8405	41.5798
OACP4 C	GDSC1; GDSC2	1.2215	20.6043	-9.3028	33.0853
ESO-51	GDSC1; GDSC2	1.9109	9.5851	-3.3084	14.4439
HCE-4	GDSC1; GDSC2	1.9643	9.3702	-3.1662	13.6444
ESO-26	GDSC1; GDSC2	2.3281	3.886	-0.5046	0.2529
KYSE-50	GDSC1; GDSC2	2.5506	4.0802	-0.4914	0.1707
OACM5.1 C	GDSC1; GDSC2	2.5894	10.6418	-3.3482	13.2053
KYSE-220	GDSC1; GDSC2	3.0517	13.9426	-4.621	17.614
TE-12	GDSC1; GDSC2	3.6874	17.6939	-5.9941	20.9891
FLO-1	GDSC1; GDSC2	5.2953	20.8376	-6.4048	19.395

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; GDSC2	-0.4632	16.5948	-8.6864	35.793

Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NB69	GDSC1; GDSC2	-6.1828	43.3411	-27.0167	51.1283
SJNB-5	GDSC1; GDSC2	-2.0946	10.2594	-6.9651	37.501
CHP-212	GDSC1; GDSC2	0.074	30.4806	-15.1787	40.7573
KP-N-YS	GDSC1; GDSC2	0.0798	13.7305	-6.7989	30.9941
SK-N-DZ	GDSC1; GDSC2	0.6253	4.8142	-1.9079	9.9618
NB(TU)1	GDSC1; GDSC2	0.6922	8.3774	-3.6267	18.8772
SK-N-BE(2)-M17	GDSC1; GDSC2	0.8208	10.27	-4.4681	22.0819
IMR-5	GDSC1; GDSC2	0.8407	4.0239	-1.3616	6.2324
SJNB-14	GDSC1; GDSC2	0.9399	16.1989	-7.3301	30.1061
SJNB-7	GDSC1; GDSC2	0.9859	10.5419	-4.4736	21.6813
GOTO	GDSC1; GDSC2	1.0484	11.6705	-4.9862	23.4018
SJNB-6	GDSC1; GDSC2	1.0568	4.3534	-1.3714	5.8319
GI-ME-N	GDSC1; GDSC2	1.4827	20.5449	-9.0644	32.1928
SK-N-MC-IXC	GDSC1; GDSC2	1.4837	9.6907	-3.6713	17.1019
KP-N-YN	GDSC1; GDSC2	1.6023	3.9127	-0.8376	2.0079
NH-12	GDSC1; GDSC2	1.6842	14.4927	-5.8951	24.7974
SiMa	GDSC1; GDSC2	1.6916	5.5057	-1.5033	5.368
TGW	GDSC1; GDSC2	1.7268	4.1015	-0.8533	1.9295
LA-N-6	GDSC1; GDSC2	1.7391	4.621	-1.0727	2.9914
SJNB-10	GDSC1; GDSC2	1.8057	8.8432	-3.0221	13.2826
SJNB-17	GDSC1; GDSC2	1.9577	4.7222	-0.9983	2.3327
SJNB-13	GDSC1; GDSC2	2.2743	3.9614	-0.5518	0.3751
MHH-NB-11	GDSC1; GDSC2	2.4261	4.1573	-0.564	0.3432
SK-N-AS	GDSC1; GDSC2	2.6068	15.605	-5.751	22.3722
SJNB-12	GDSC1; GDSC2	2.8194	14.0045	-4.8144	18.7976
KP-N-RT-BM-1	GDSC2	2.9561	4.9411	-0.6432	0.3374
SK-N-FI	GDSC1; GDSC2	3.302	14.3134	-4.6268	17.145
SK-N-SH	GDSC1; GDSC2	3.9815	16.6825	-5.3017	18.2605
KP-N-SI9s	CTRP2	5.9927	51.0653	-16.5091	41.1108
NB1	GDSC1; GDSC2; CTRP2	6.0207	26.6696	-4.288	30.5796
Kelly	GDSC1; GDSC2; CTRP2	6.8025	42.2982	-11.4547	36.7674
CHP-126	GDSC1; GDSC2; CTRP2	10.6031	31.0943	-2.9144	21.5114

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-1079	CTRP2	2.0478	18.3045	-3.6682	39.2245
HuCC-T1	GDSC1; GDSC2; CTRP2	3.2721	18.8936	-2.8152	33.4136
SNU-1196	CTRP2	7.2226	9.533	5.1567	1.9773
SNU-478	CTRP2	7.3373	29.0942	-4.4215	29.9328
HuH-28	CTRP2	8.5035	19.3467	1.3147	14.667
SNU-308	CTRP2	9.8876	31.3197	-3.5509	24.7102

Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MDA-MB-330	GDSC1; GDSC2	-3.9789	36.0063	-21.4178	48.3874
DU4475	GDSC1; GDSC2	-0.9043	20.4835	-11.0048	39.4728
MDA-MB-361	GDSC1; GDSC2	-0.8356	11.5918	-6.5062	32.79
MRK-nu-1	GDSC1; GDSC2	-0.6597	13.5738	-7.3442	34.0405
HCC1569	GDSC1; GDSC2; CTRP2	-0.4726	9.2889	-2.1577	42.6463
HCC1500	GDSC1; GDSC2	-0.2592	17.5937	-9.0138	35.7943
Hs 578T	GDSC1; GDSC2	-0.2269	55.9746	-28.1766	45.2085
HCC1954	GDSC1; GDSC2; CTRP2	-0.2209	10.0389	-2.1845	41.8022
EFM-19	GDSC1; GDSC2	-0.2131	16.639	-8.4977	34.9203
MDA-MB-453	GDSC1; GDSC2	-0.1462	6.1865	-3.2159	19.2654
HCC1419	GDSC1; GDSC2	0.1078	28.9558	-14.3881	40.2207
MDA-MB-415	GDSC1; GDSC2	0.1542	59.6967	-29.72	45.1268
HCC2157	GDSC1; GDSC2	0.4142	9.9649	-4.6416	23.8113
EFM-192A	GDSC1; GDSC2	0.4244	21.3159	-10.3064	36.0363
HCC202	GDSC1	0.4346	2.9492	-3.1656	1.231
T-47D	GDSC1; GDSC2	0.4641	19.4562	-9.3441	34.6899
ZR-75-1	CTRP2	0.504	23.2323	-7.5128	45.4615
MDA-MB-175-VII	GDSC1; GDSC2	0.5721	11.3286	-5.1949	25.319
UACC-893	GDSC1; GDSC2	0.5809	11.4482	-5.2475	25.4677
OCUB-M	GDSC1; GDSC2	0.6071	20.6077	-9.8024	35.03
CAL-85-1	GDSC1; GDSC2	0.7926	7.4239	-3.0739	15.9528
MCF-7	GDSC1; GDSC2; CTRP2	0.9283	15.5521	-3.4383	39.8659
Evsa-T	GDSC1; GDSC2	1.0283	28.1181	-13.2116	37.8731
MFM-223	GDSC1; GDSC2	1.0377	13.5352	-5.9235	26.3851
ZR-75-30	GDSC1; GDSC2	1.1401	8.4617	-3.3224	16.3054
CAL-148	GDSC2; CTRP2	1.1573	55.7355	-22.9828	46.8931
BT-549	GDSC1; GDSC2	1.2134	31.7773	-14.8891	38.8612
UACC-812	GDSC2	1.2677	26.3647	-12.1414	36.8447
AU565	GDSC1; GDSC2	1.2784	17.9147	-7.9155	30.5629
YMB-1-E	GDSC2	1.3168	19.0961	-8.4741	31.9548
COLO 824	GDSC1; GDSC2	1.317	3.7408	-0.9203	2.8287
MDA-MB-468	GDSC1; GDSC2	1.3301	18.5513	-8.1919	30.983
BT-474	GDSC1; GDSC2	1.4456	14.9173	-6.2908	26.4504
BT-483	GDSC1; GDSC2	1.7984	20.0981	-8.5924	30.7642
MDA-MB-157	GDSC1; GDSC2	1.8325	6.2565	-1.7648	6.5512
HCC70	GDSC1; GDSC2	2.0325	27.8602	-12.2746	35.3749
HCC38	GDSC1; GDSC2	2.2014	13.8237	-5.174	21.3681
HCC1599	GDSC2	2.3114	4.1131	-0.5925	0.4769
CAL-51	GDSC1; GDSC2; CTRP2	2.3589	28.5586	-8.4145	41.0183
MDA-MB-436	GDSC1; GDSC2	2.6988	19.7034	-7.7029	27.2465
BT-20	GDSC1; GDSC2	2.7185	27.8439	-11.7264	33.6705
HCC2218	GDSC1; GDSC2	2.745	14.6845	-5.1993	20.3043
HCC1143	GDSC1; GDSC2; CTRP2	2.7456	17.8895	-2.8106	34.5706
HCC1187	GDSC1; GDSC2	2.9179	15.1646	-5.3095	20.3228
HCC1428	GDSC1; GDSC2	3.3282	13.9864	-4.4516	16.4284
HCC1806	GDSC1; GDSC2; CTRP2	4.3394	5.0648	4.3356	10.4294
CAL-120	GDSC1; GDSC2; CTRP2	4.559	5.528	4.5296	9.1675
HDQ-P1	GDSC1; GDSC2; CTRP2	4.82	10.3109	2.821	14.7426
JIMT-1	GDSC1; GDSC2; CTRP2	5.0974	12.8517	1.8225	17.7622
KPL-1	CTRP2	5.7024	25.7337	-4.0867	32.1707
CAMA-1	GDSC1; GDSC2; CTRP2	6.6593	40.9685	-10.9079	36.5587
HCC1395	GDSC1; GDSC2; CTRP2	8.1429	28.6033	-3.5375	26.0488
MDA-MB-231	GDSC1; GDSC2; CTRP2	10.6921	41.5266	-7.9879	29.095
HCC1937	GDSC1; GDSC2; CTRP2	11.0705	39.6418	-6.7717	27.1715
HMC-1-8	CTRP2	13.169	35.2408	-3.1279	19.7687

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	15.545	36.8233	-2.3321	15.6019

Cancer Drug Sensitivity Data Curated from 63 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PFSK-1	GDSC1	-5.7127	8.5492	-10.7896	47.7265
D-566MG	GDSC1; GDSC2	-0.8864	55.9487	-28.7164	45.8916
YH-13	GDSC1; GDSC2	-0.5176	35.9644	-18.4154	43.1081
U-118MG	GDSC1; GDSC2	-0.3967	53.4632	-27.0629	45.1739
MOG-G-UVW	GDSC1; GDSC2	-0.3857	38.3333	-19.489	43.3134
H4	GDSC1; GDSC2	-0.3525	237.5137	-119.0507	48.89
SW1783	GDSC1; GDSC2	-0.3488	7.3483	-3.9687	23.3415
D-336MG	GDSC1; GDSC2	-0.3167	23.6564	-12.0931	39.2688
SF539	GDSC1; GDSC2	-0.226	16.4382	-8.4082	34.8092
LNZTA3WT4	GDSC1; GDSC2	-0.2064	26.6113	-13.4781	40.1296
SK-MG-1	GDSC1; GDSC2	-0.1854	18.7351	-9.5225	36.3193
YKG-1	GDSC1; GDSC2	-0.185	16.9327	-8.621	35.046
T98G	GDSC1; GDSC2	-0.0522	15.0099	-7.5485	32.8881
D-247MG	GDSC1; GDSC2	-0.0274	27.8694	-13.9575	40.157
KNS-42	GDSC1; GDSC2	0.0455	14.8151	-7.3697	32.2975
MOG-G-CCM	GDSC1; GDSC2	0.103	33.0837	-16.4561	41.4034
42-MG-BA	GDSC1; GDSC2	0.1065	35.0126	-17.4176	41.8554
Becker	GDSC1; GDSC2	0.1764	30.0492	-14.8778	40.4202
SF295	GDSC1; GDSC2; CTRP2	0.208	28.881	-10.5402	45.6566
M059J	GDSC1; GDSC2	0.2297	63.3666	-31.4921	45.3361
D-263MG	GDSC1; GDSC2	0.2431	18.1419	-8.8692	34.4625
A-172	GDSC1; GDSC2	0.3675	35.7935	-17.5914	41.5804
KNS-81-FD	GDSC1; GDSC2	0.4054	18.8966	-9.1126	34.4772
KS-1 [Human Krukenberg tumour]	GDSC1; GDSC2	0.4648	20.6454	-9.9379	35.4951
GI-1	GDSC1; GDSC2	0.606	23.6458	-11.3217	36.833
SF268	GDSC1; GDSC2	0.704	13.7075	-6.2763	28.1616
SNB-75	GDSC1; GDSC2	0.7574	19.3732	-9.0629	33.6603
D-392MG	GDSC1; GDSC2	0.7609	27.6254	-13.1839	38.2864
D-423MG	GDSC1; GDSC2	0.8024	13.3812	-6.0342	27.2679
AM-38	GDSC1; GDSC2	0.836	20.6902	-9.6569	34.3717
Onda 10	GDSC1; GDSC2	0.8373	6.3447	-2.5045	12.8323
LN-405	GDSC1; GDSC2	0.9256	25.0061	-11.7403	36.6893
Hs 683	GDSC1; GDSC2	0.9663	34.7902	-16.5965	40.2661
D-542MG	GDSC1; GDSC2	1.0647	25.8475	-12.0476	36.7549
DK-MG	GDSC1; GDSC2	1.2837	19.2813	-8.5928	31.8019
8-MG-BA	GDSC1; GDSC2	1.3081	26.8565	-12.3543	36.6418
D-245MG	GDSC2	1.5366	12.8597	-5.1984	23.4359
U-251MG	GDSC1; GDSC2	1.5944	13.2879	-5.3665	23.3711
KINGS-1	GDSC1; GDSC2	1.6276	20.2136	-8.7844	31.4389
D283 Med	GDSC1; GDSC2	2.1912	11.6207	-4.1009	17.3522
D-502MG	GDSC1; GDSC2	2.6335	18.0014	-6.9113	25.5309
SNU-738	CTRP2	4.135	11.3649	1.6633	22.0598
SNU-626	CTRP2	4.2747	5.4813	4.2326	11.9329
GaMG	GDSC1; GDSC2; CTRP2	4.8114	65.2256	-24.5799	43.7594
CAS-1	GDSC1; GDSC2; CTRP2	5.0145	27.3044	-5.4556	33.8386
NMC-G1	GDSC1; GDSC2; CTRP2	5.4987	6.182	5.4064	3.6371
KNS-81	CTRP2	5.756	29.7117	-6.0304	34.5752
Onda 11	GDSC1; GDSC2	6.0925	26.1836	-8.4281	23.1059
SW1088	GDSC1; GDSC2; CTRP2	6.749	61.4904	-21.0936	41.251
SNU-201	CTRP2	7.5819	9.6971	5.2843	1.1825
SNU-489	CTRP2	8.0544	18.9619	1.1747	15.8458
GB-1	GDSC1; GDSC2; CTRP2	9.0925	30.2633	-3.6281	24.8601
KNS-60	CTRP2	9.2541	40.5123	-8.5932	32.3683
ONS-76	GDSC1; GDSC2; CTRP2	9.763	38.9429	-7.4179	29.5159
SNU-466	CTRP2	9.7863	25.0774	-0.5626	18.2965
KALS-1	GDSC1; GDSC2; CTRP2	9.8574	42.9739	-9.3468	31.4788
SF126	GDSC1; GDSC2; CTRP2	11.6775	40.9857	-6.9828	26.7595
SNU-1105	CTRP2	12.4587	31.5545	-1.8423	17.8994
Daoy	GDSC1; GDSC2; CTRP2	12.716	41.3655	-6.4119	24.8522
LN-18	GDSC1; GDSC2; CTRP2	14.1915	34.9054	-2.2925	16.1289
DBTRG-05MG	GDSC1; GDSC2; CTRP2	14.5909	32.044	-0.7119	12.176
U-87MG ATCC	GDSC1; CTRP2	14.8834	36.2864	-2.498	15.8621
LN-229	GDSC1; GDSC2; CTRP2	15.4741	35.3072	-1.6748	13.5473

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC1; GDSC2	0.2616	39.1281	-19.3464	42.4479
TGBC1TKB	GDSC1; GDSC2	0.3671	20.7174	-10.0544	35.8407
TGBC24TKB	GDSC1; GDSC2	1.9338	4.0667	-0.7369	1.2026

Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MFE-319	GDSC1; GDSC2	-7.5532	172.2236	-92.4844	50.7307
MFE-296	GDSC1; GDSC2	-5.8935	10.4907	-10.7085	52.3606
JHUEM-2	CTRP2	-5.8814	34.4037	-18.9855	55.9176
MFE-280	GDSC1; GDSC2	1.716	7.1279	-2.2552	9.4682
EN	GDSC1; GDSC2	1.9059	20.3053	-8.6113	30.5866
KLE	GDSC1; GDSC2; CTRP2	3.3899	5.6792	3.2384	16.6992
ESS-1	GDSC1; GDSC2	3.6973	34.7647	-14.4054	34.9817
RL95-2	GDSC1; GDSC2; CTRP2	3.7827	39.9629	-12.8346	41.2785
AN3-CA	GDSC1; GDSC2	3.8638	25.9814	-9.928	29.3479
HEC-151	CTRP2	7.1827	20.8822	-0.4485	22.1683
HEC-265	CTRP2	7.6498	8.7926	5.6721	0.1547
HEC-59	CTRP2	8.2744	59.4943	-18.8457	39.793
EFE-184	CTRP2	8.434	23.2517	-0.658	20.6023
HEC-1-B	CTRP2	12.3796	28.3824	-0.3893	14.4586
HEC-6	CTRP2	12.9351	40.5612	-5.863	24.6917
HEC-251	CTRP2	13.2887	44.6749	-7.6167	26.6745
HEC-50B	CTRP2	13.5008	42.535	-6.422	24.8728
HEC-108	CTRP2	17.201	42.9326	-4.1382	17.5161
Ishikawa (Heraklio) 02 ER-	CTRP2	15.5672	41.4332	-4.482	19.6903

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KTCTL-195	GDSC1; GDSC2	-8.7285	186.1438	-100.4421	51.0052
786-O	GDSC1; GDSC2	-3.0434	14.2691	-9.8063	43.5463
KTCTL-26A	GDSC1; GDSC2	-2.9645	20.7853	-12.956	45.0304
KTCTL-140	GDSC1; GDSC2	-2.0333	24.0036	-13.7357	43.5396
LB1047-RCC	GDSC1; GDSC2	-0.9788	10.8433	-6.2575	32.6313
KTCTL-1M	GDSC1; GDSC2	-0.7559	28.479	-14.8742	41.8965
RXF 393L	GDSC1; GDSC2	-0.7007	40.4803	-20.827	44.1151
BB65-RCC	GDSC1; GDSC2	-0.6597	45.5981	-23.3511	44.7013
KMRC-1	GDSC1; GDSC2	-0.4856	20.6609	-10.7379	38.3509
LB2241-RCC	GDSC1; GDSC2	-0.2968	13.742	-7.1199	32.6508
SN12C	GDSC1; GDSC2	-0.1893	10.6639	-5.4905	28.3083
SW156	GDSC1; GDSC2	-0.1804	18.2817	-9.2916	36.0021
VMRC-RCZ	GDSC1; GDSC2	-0.1731	15.4405	-7.865	33.768
SW13	GDSC1; GDSC2	0.1764	14.4813	-7.0942	31.4035
KTCTL-13	GDSC1; GDSC2	0.3059	17.4611	-8.477	33.7013
CAL-54	GDSC1; GDSC2	0.4221	20.0215	-9.6612	35.2172
A-498	GDSC1; GDSC2	0.5789	12.7573	-5.9029	27.4573
NCC010	GDSC1; GDSC2	0.7728	10.4469	-4.5942	22.6858
HA7-RCC	GDSC1; GDSC2	0.9227	17.9128	-8.1996	31.8635
LB996-RCC	GDSC2	1.191	9.7845	-3.9386	19.4799
NCC021	GDSC1; GDSC2	1.2732	11.9255	-4.9377	22.6812
KTCTL-21	GDSC1; GDSC2	2.0993	11.7756	-4.2431	18.1357
UO-31	GDSC1; GDSC2	2.2435	13.417	-4.943	20.4737
A-704	GDSC1; GDSC2	2.2734	26.0477	-11.1812	33.7422
Caki-1	GDSC1; GDSC2	3.7014	21.1004	-7.647	25.2663
TK-10	GDSC1; GDSC2	4.025	18.8286	-6.3075	21.2826
TUHR4TKB	CTRP2	4.4184	5.6457	4.3607	11.0297
RCC10RGB	GDSC1; GDSC2	4.9085	19.5172	-6.0332	18.9542
ACHN	GDSC1; GDSC2	4.9695	24.4189	-8.3566	24.676
BFTC-909	GDSC1; GDSC2; CTRP2	6.7461	20.7245	-0.7194	22.2884
VMRC-RCW	GDSC1; GDSC2; CTRP2	7.097	10.2705	4.7311	3.4747
TUHR10TKB	CTRP2	7.5104	9.0375	5.5217	0.5303
OS-RC-2	GDSC1; GDSC2; CTRP2	8.0001	43.6705	-11.1648	35.1599
SNU-1272	CTRP2	11.4149	42.473	-7.9108	29.0832
769-P	GDSC1; GDSC2; CTRP2	12.0519	31.2135	-1.9539	17.735
KMRC-20	GDSC1; GDSC2; CTRP2	13.5895	32.7488	-1.6652	15.391

Cancer Drug Sensitivity Data Curated from 51 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-81	GDSC1; GDSC2	-0.7882	41.7244	-21.5227	44.4066
SW948	GDSC1; GDSC2	0.5295	3.4634	-1.3127	6.6509
SW1417	GDSC1; GDSC2	0.6565	4.1674	-1.5651	7.8585
HCT 15	GDSC1; GDSC2	0.9009	16.0205	-7.2724	30.0704
RCM-1 [Human ESC]	GDSC1; GDSC2	0.9703	2.8407	-0.7164	2.2889
SNU-175	GDSC2	1.1048	3.2523	-0.8238	2.7446
GP5d	GDSC1; GDSC2	1.1664	8.6677	-3.4043	16.6323
CaR-1	GDSC1; GDSC2	1.197	8.205	-3.1526	15.3371
C2BBe1	GDSC1; GDSC2	1.3675	8.8729	-3.3547	15.9097
COLO 320HSR	GDSC1; GDSC2	1.5241	10.5047	-4.0426	18.6241
LS1034	GDSC1; GDSC2	1.6609	3.3639	-0.5814	0.8329
SW837	GDSC1; GDSC2	1.6647	4.6366	-1.1219	3.356
COLO 678	GDSC1; GDSC2	1.6713	4.069	-0.8684	2.069
SNU-283	GDSC2	1.7258	3.1334	-0.4653	0.4206
SW626	GDSC1; GDSC2	1.728	12.989	-5.1166	22.2301
T84	GDSC1; GDSC2	1.8115	3.87	-0.7148	1.2259
SW1463	GDSC1; GDSC2	2.041	3.9756	-0.6526	0.8012
NCI-H747	GDSC1; GDSC2	2.1438	10.473	-3.5753	15.1752
SNU-C1	GDSC1; GDSC2	2.2945	4.2882	-0.6644	0.6746
HCC2998	GDSC1; GDSC2	2.4444	10.354	-3.3087	13.3145
LS123	GDSC1; GDSC2; CTRP2	2.8791	12.6074	-0.1419	28.776
SNU-C2B	GDSC1; GDSC2	3.0293	13.2268	-4.2907	16.3818
SK-CO-1	GDSC1; GDSC2; CTRP2	3.1922	20.4741	-3.6664	34.881
DiFi	GDSC1; GDSC2	3.361	19.5849	-7.1522	24.724
SW620	GDSC1; GDSC2; CTRP2	3.6158	15.512	-0.8395	28.7451
LoVo	GDSC1; GDSC2; CTRP2	4.1097	29.2609	-7.2131	37.1863
SW1116	GDSC1; GDSC2; CTRP2	4.3218	14.0798	0.5141	23.593
OUMS-23	CTRP2	4.4176	8.9152	3.1001	15.901
NCI-H716	GDSC1; GDSC2	4.5786	23.8219	-8.3443	25.2812
DLD-1	CTRP2	4.6621	5.0984	4.6618	9.21
SW48	GDSC1; GDSC2; CTRP2	4.7815	19.3437	-1.6849	28.1629
LS513	GDSC1; GDSC2; CTRP2	4.7981	15.4302	0.2763	23.2738
CL-11	GDSC1; GDSC2; CTRP2	4.8773	17.3696	-0.618	25.5089
SNU-407	GDSC1; GDSC2; CTRP2	4.9014	21.774	-2.7921	30.0897
SNU-C5	GDSC1; GDSC2; CTRP2	5.6298	21.5154	-2.0393	27.2906
SNU-61	GDSC1; GDSC2; CTRP2	5.8425	8.6223	4.5836	5.9992
HT115	GDSC1; GDSC2; CTRP2	5.899	21.4097	-1.7598	26.2141
KM12	GDSC1; GDSC2; CTRP2	5.9185	17.6326	0.1451	21.4532
LS411N	GDSC1; GDSC2; CTRP2	5.9679	6.8873	5.5576	2.0166
COLO205	GDSC1; GDSC2; CTRP2	6.4753	9.5651	4.629	4.7395
MDST8	GDSC1; GDSC2; CTRP2	7.1838	104.7589	-42.3666	44.7856
HT-29	GDSC1; GDSC2; CTRP2	7.6026	8.8762	5.6232	0.2331
HCT 116	GDSC1; GDSC2; CTRP2	7.7837	9.3751	5.5103	0.3837
CCK-81	GDSC1; GDSC2; CTRP2	7.8496	10.8658	4.92	1.9945
SNU-C2A	CTRP2	8.3209	45.8938	-12.0163	36.2798
NCI-H508	GDSC1; GDSC2; CTRP2	8.8329	36.0657	-6.7104	29.8146
CW-2	GDSC1; GDSC2; CTRP2	8.8766	16.349	3.0181	7.4289
HT-55	GDSC1; GDSC2; CTRP2	9.4176	20.4729	1.411	12.0979
COLO201	CTRP2	9.7675	23.3322	0.2723	16.0165
LS180	GDSC1; GDSC2; CTRP2	12.9076	29.1731	-0.4232	13.1594
RKO	GDSC1; GDSC2; CTRP2	16.4615	46.5775	-6.3361	21.0335

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1; GDSC2	1.7497	5.7415	-1.5766	5.6677

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-387	GDSC1; GDSC2	-1.0884	9.9341	-5.9009	32.0858
SK-HEP-1	GDSC1; GDSC2	-0.7679	6.2182	-3.7702	23.8057
Huh-7	GDSC1; GDSC2	-0.2439	30.0368	-15.2222	41.2724
HLE	GDSC1; GDSC2	0.2035	25.3825	-12.5221	38.6866
JHH-2	GDSC1; GDSC2	0.3208	37.4252	-18.4459	42.0156
JHH-4	GDSC1; GDSC2	0.4918	9.6009	-4.397	22.6738
SNU-423	GDSC1; GDSC2	0.8737	22.1136	-10.3374	35.1993
JHH-1	GDSC1; GDSC2	0.8908	37.688	-18.1069	41.1308
SNU-878	CTRP2	0.9294	13.5997	-2.5357	40.9761
SNU-449	GDSC1; GDSC2	0.9345	8.9349	-3.7146	18.6468
JHH-7	GDSC1; GDSC2	1.0307	9.8451	-4.0921	20.0373
SNU-182	CTRP2	1.4041	23.0353	-6.572	43.1004
Hep-G2/C3A	GDSC1; GDSC2	1.4785	4.7947	-1.3058	4.6551
HuH-1	GDSC1; GDSC2	1.6018	14.6492	-6.0362	25.3912
HuH-6	CTRP2	1.9442	12.1676	-0.8639	35.2227
SNU-886	CTRP2	2.4428	7.2094	1.7438	32.7607
Li-7	CTRP2	2.9988	30.5241	-8.8178	41.44
SNU-761	CTRP2	3.3792	64.0667	-25.2167	45.6569
SNU-398	GDSC1; GDSC2; CTRP2	4.0847	26.4847	-5.8516	35.8821
JHH-6	GDSC1; GDSC2	4.8294	16.1499	-4.4926	13.9273
Hep-G2	CTRP2	10.8798	28.5069	-1.4569	19.0064
Hep 3B2.1-7	GDSC1; GDSC2; CTRP2	14.2196	36.0325	-2.8064	17.1566

Cancer Drug Sensitivity Data Curated from 205 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H841	GDSC1; GDSC2	-4.0519	13.7649	-10.4947	46.6963
NCI-H2369	GDSC1; GDSC2	-3.9377	26.5645	-16.6914	47.8234
NCI-H838	GDSC1; GDSC2	-3.6795	22.6565	-14.5239	46.9606
EBC-1	GDSC1; GDSC2; CTRP2	-3.2878	30.4877	-14.6183	51.825
IST-SL2	GDSC1; GDSC2	-1.1908	13.3986	-7.7158	36.1176
NCI-H1184	CTRP2	-1.1828	8.5436	-2.6431	48.7229
HOP-62	GDSC1; GDSC2	-0.9707	9.5427	-5.6027	30.9308
DMS 114	GDSC1; GDSC2	-0.943	17.207	-9.4015	37.8728
SBC-1	GDSC1; GDSC2	-0.8133	18.8257	-10.0989	38.3771
EMC-BAC-2	GDSC1; GDSC2	-0.7203	20.8964	-11.0543	39.1394
UMC-11	GDSC1; GDSC2	-0.692	11.3371	-6.2551	31.7941
NCI-H290	GDSC1; GDSC2	-0.5759	21.1177	-11.0426	38.8346
RERF-LC-MS	GDSC1; GDSC2	-0.5276	4.7117	-2.8088	18.333
NCI-H1975	GDSC1; GDSC2	-0.402	14.5309	-7.6031	33.8603
NCI-H720	GDSC1; GDSC2	-0.2682	13.9293	-7.1894	32.7198
NCI-H2795	GDSC1; GDSC2	-0.1705	45.2118	-22.7482	44.0194
NCI-H211	GDSC1; GDSC2; CTRP2	-0.1494	16.7628	-5.0673	44.1104
NCI-H1703	GDSC1; GDSC2	-0.1445	30.0126	-15.1269	41.0645
NCI-H187	GDSC1	-0.0884	5.2378	-4.442	9.7097
Calu-3	GDSC1; GDSC2; CTRP2	-0.0591	15.0135	-4.1727	43.2447
NCI-H1437	GDSC1; GDSC2	-0.0293	14.6282	-7.3385	32.4191
Lu-139	GDSC1; GDSC2	-0.0013	18.9502	-9.4762	35.86
NCI-H460	GDSC1; GDSC2; CTRP2	0.0932	166.3294	-79.1099	49.2633
A-427	GDSC1; GDSC2	0.1157	14.7689	-7.2882	31.9598
HCC44	GDSC1; GDSC2; CTRP2	0.1257	13.4094	-3.2623	41.9065
NCI-H1563	GDSC1; GDSC2	0.1318	17.8973	-8.839	34.6619
SBC-3	GDSC1; GDSC2	0.1637	15.5642	-7.6461	32.5531
NCI-H1648	GDSC1; GDSC2	0.1716	6.9654	-3.3407	18.9542
NCI-H2373	GDSC1; GDSC2	0.1932	36.4036	-18.0411	42.012
NCI-H2170	GDSC1; GDSC2	0.2225	34.6132	-17.1216	41.5592
NCI-H1693	GDSC1; GDSC2	0.2301	17.0964	-8.3572	33.6726
NCI-H1944	GDSC1; GDSC2	0.297	21.2006	-10.3538	36.3461
Lu-134-A	GDSC1; GDSC2	0.3725	12.1385	-5.7617	27.5841
NCI-H647	GDSC1; GDSC2	0.3898	11.0843	-5.2208	25.8834
NCI-H2171	GDSC2	0.4304	10.3792	-4.8354	25.0281
NCI-H1304	GDSC1	0.4658	10.6706	-6.6671	19.9655
NCI-H209	GDSC1; GDSC2	0.5171	15.8754	-7.511	31.4543
COR-L279	GDSC1; GDSC2	0.5586	4.2533	-1.6809	8.7844
NCI-H2196	GDSC2	0.5695	11.7949	-5.4298	26.6197
NCI-H847	GDSC1; GDSC2	0.6459	3.5496	-1.2696	6.1215
RERF-LC-Sq1	GDSC1; GDSC2	0.6523	24.9164	-11.9189	37.3497
COR-L105	GDSC1; GDSC2	0.6549	39.0599	-18.9869	41.8153
KNS-62	GDSC1; GDSC2	0.6645	29.3675	-14.1338	39.1665
NCI-H2066	GDSC1; GDSC2	0.6685	11.0872	-4.9968	24.4026
RERF-LC-KJ	GDSC1; GDSC2	0.6964	24.6525	-11.7508	37.1067
NCI-H1869	GDSC1	0.7156	12.0487	-7.1602	21.2889
Calu-6	GDSC1; GDSC2; CTRP2	0.7403	5.9971	0.2687	33.7775
NCI-H2591	GDSC1; GDSC2	0.7453	15.2165	-6.9964	29.8187
Lu-99A	GDSC1; GDSC2	0.8275	17.3894	-8.0151	31.7308
COR-L303	GDSC2	0.8304	9.0593	-3.8576	20.0669
NCI-H1993	GDSC1; GDSC2	0.8374	8.1068	-3.3784	17.3358
COR-L32	GDSC2	0.8389	14.0157	-6.3216	28.4588
SK-MES-1	GDSC1; GDSC2	0.8468	9.1763	-3.9029	19.7029
NCI-H2810	GDSC1; GDSC2	0.8504	13.5029	-6.0565	27.2123
NCI-H524	GDSC1; GDSC2; CTRP2	0.8563	6.2769	0.3173	33.2747
LK-2	GDSC1; GDSC2	0.8613	14.9433	-6.7666	29.0111
NCI-H358	GDSC1; GDSC2; CTRP2	0.8702	14.8784	-3.1825	39.7218
NCI-H2087	GDSC1; GDSC2; CTRP2	0.8722	11.229	-1.5381	37.3356
NCI-H835	GDSC1; GDSC2	0.8853	6.4785	-2.5343	12.8765
NCI-H596	GDSC1; GDSC2	0.8925	8.6389	-3.6001	18.2342
EPLC-272H	GDSC1; GDSC2; CTRP2	1.0374	22.1587	-6.4893	42.2638
NCI-H1155	GDSC1; GDSC2; CTRP2	1.0479	17.2329	-4.1128	40.288
NCI-H3255	GDSC1; GDSC2	1.0589	12.3743	-5.3284	24.523
NCI-H810	GDSC1; GDSC2	1.0866	11.1606	-4.7026	22.2927
NCI-H1793	GDSC1; GDSC2	1.1383	24.0656	-11.0979	35.6174
VMRC-LCD	GDSC1; GDSC2	1.1513	15.1627	-6.6445	28.0387
LC-2/ad	GDSC1; GDSC2	1.1673	11.6228	-4.8695	22.6979
Lu-65	GDSC1; GDSC2	1.2436	10.5477	-4.2767	20.2635
Ms-1	GDSC1; GDSC2	1.3124	9.6411	-3.7753	17.9772
HOP-92	GDSC1; GDSC2	1.3267	9.8775	-3.8814	18.4078
COR-L311	GDSC2	1.329	9.2267	-3.558	17.4215
COR-L88	GDSC1; GDSC2	1.386	8.9416	-3.3749	15.9617
EKVX	GDSC1; GDSC2	1.3906	25.455	-11.588	35.717
NCI-H250	GDSC2	1.4618	12.9357	-5.2937	23.9316
IA-LM	GDSC1; GDSC2	1.4629	16.0657	-6.8486	27.8356
NCI-H2803	GDSC1; GDSC2	1.4648	5.3336	-1.5672	6.1425
COLO 668	GDSC1; GDSC2	1.4707	4.3808	-1.12	3.6518
NCI-H522	GDSC2	1.4987	6.4807	-2.0924	9.328
NCI-H1105	GDSC1; GDSC2	1.5002	7.6924	-2.6789	12.2052
NCI-H345	GDSC1; GDSC2	1.5037	2.27	-0.2441	0.045
NCI-H748	GDSC2	1.505	3.5808	-0.7463	1.7544
HCC33	GDSC2	1.5159	3.3602	-0.6481	1.2814
NCI-H2141	GDSC1; GDSC2	1.5236	3.0795	-0.5309	0.7549
NCI-H1436	GDSC1; GDSC2	1.5356	3.2725	-0.6027	1.026
EMC-BAC-1	GDSC1; GDSC2	1.5405	19.9449	-8.7195	31.5007
COR-L95	GDSC1; GDSC2	1.5432	3.303	-0.6114	1.0547
NCI-H1341	GDSC1; GDSC2	1.6399	11.7884	-4.5896	20.5367
NCI-H1651	GDSC1; GDSC2	1.6449	9.6144	-3.5148	16.011
NCI-H1781	GDSC1; GDSC2	1.6831	12.3302	-4.8247	21.3069
NCI-H2029	GDSC1; GDSC2	1.7129	4.3014	-0.9467	2.3959
ChaGo-K-1	GDSC1; GDSC2	1.7182	5.9391	-1.6888	6.344
NCI-H1581	GDSC1; GDSC2; CTRP2	1.7621	17.2367	-3.4256	37.753
NCI-H520	GDSC1; GDSC2; CTRP2	1.7973	16.7134	-3.1413	37.2906
Lu-165	GDSC1; GDSC2	1.7999	7.6571	-2.4522	10.3544
NCI-H1963	GDSC1; GDSC2	1.8139	6.4912	-1.887	7.257
NCI-H1734	GDSC1; GDSC2; CTRP2	1.8367	12.4856	-1.117	33.7706
NCI-H1770	GDSC1; GDSC2	1.8387	5.0886	-1.2245	3.6281
NCI-H292	GDSC1; GDSC2; CTRP2	1.8413	38.5133	-13.8133	44.1809
NCI-H1915	GDSC1; GDSC2	1.8905	18.7972	-7.8733	29.2039
NCI-H1876	GDSC1; GDSC2	1.8961	6.7823	-1.9711	7.5615
LB647-SCLC	GDSC1; GDSC2	1.9078	3.8658	-0.6686	0.9596
NCI-H2227	GDSC1; GDSC2	1.9408	6.948	-2.0203	7.7442
COR-L321	GDSC1; GDSC2	2.0096	7.8091	-2.3834	9.5617
NCI-H2135	GDSC1; GDSC2	2.0154	3.5752	-0.5125	0.3909
NCI-H740	GDSC2	2.0449	9.3017	-3.0766	13.414
NCI-H3122	GDSC1; GDSC2	2.0595	15.3728	-6.0448	24.4036
NCI-H1092	GDSC1; GDSC2	2.0676	6.861	-1.8986	6.8516
NCI-H2818	GDSC1; GDSC2	2.0952	43.5176	-20.0384	40.5515
NCI-H1355	GDSC1; GDSC2; CTRP2	2.1296	28.7278	-8.7049	41.5838
NCI-H2731	GDSC1; GDSC2	2.1919	14.6401	-5.5833	22.7282
ABC-1	GDSC1; GDSC2	2.2527	27.9852	-12.1624	34.9032
NCI-H1666	GDSC1; GDSC2; CTRP2	2.2759	26.9477	-7.6929	40.6892
COR-L23	GDSC1; GDSC2	2.2772	15.8477	-6.1154	24.1405
NCI-H2106	CTRP2	2.3465	5.1668	2.2101	25.1012
DMS 273	GDSC1; GDSC2	2.3636	15.0122	-5.6389	22.5345
NCI-H146	GDSC1; GDSC2	2.3676	17.7576	-6.9912	26.2629
NCI-H1623	GDSC1; GDSC2	2.3861	15.9336	-6.0762	23.7989
NCI-H2110	GDSC1; GDSC2	2.4016	19.3607	-7.759	27.9443
NCI-H1836	GDSC1; GDSC2	2.4506	4.1213	-0.542	0.2878
NCI-H23	GDSC1; GDSC2	2.486	11.6061	-3.8845	15.8108
NCI-H2804	GDSC1; GDSC2	2.6185	14.4485	-5.1752	20.4842
NCI-H513	GDSC1; GDSC2	2.675	17.9818	-6.8706	25.3464
NCI-H82	GDSC1; GDSC2	2.7045	18.6011	-7.1541	25.9831
NCI-H1694	GDSC1; GDSC2	2.7117	13.9626	-4.8707	19.223
DMS 53	GDSC1; GDSC2	2.7332	4.9591	-0.7358	0.6397
PaCa-3	GDSC1; GDSC2	2.743	16.9991	-6.336	23.8001
Sq-1	CTRP2	2.7778	9.7994	1.0454	27.7729
CPC-N	GDSC1; GDSC2	2.8521	16.5756	-6.0477	22.7611
NCI-H889	CTRP2	2.9471	20.45	-3.8784	37.3663
Lu-135	GDSC1; GDSC2	2.9735	15.5684	-5.4667	20.7282
LCLC-97TM1	GDSC1; GDSC2; CTRP2	2.9984	15.6174	-1.4689	31.5574
NCI-H2722	GDSC1; GDSC2	3.1715	18.2027	-6.6125	23.7084
NCI-H64	GDSC1; GDSC2	3.1939	12.6789	-3.9159	14.5283
NCI-H510A	GDSC1; GDSC2	3.2315	15.7973	-5.3944	19.9815
NCI-H1573	GDSC1; GDSC2; CTRP2	3.3067	9.3903	1.7666	21.9559
NCI-H2342	GDSC1; GDSC2	3.3447	22.1076	-8.4052	27.5106
NCI-H2081	GDSC1; GDSC2	3.3674	20.9538	-7.8201	26.2523
SW1271	GDSC1; GDSC2; CTRP2	3.4289	20.4741	-3.4513	34.078
NCI-H2461	GDSC1; GDSC2	3.7801	40.0166	-16.9519	36.8684
IST-SL1	GDSC1; GDSC2	4.0437	15.7172	-4.7978	16.3949
LC-1/sq	GDSC1; GDSC2	4.19	19.9499	-6.7355	22.1629
NCI-H1568	GDSC1; GDSC2	4.3014	20.526	-6.9367	22.4935
NCI-H1755	GDSC1; GDSC2; CTRP2	4.3346	21.4797	-3.1406	31.775
SBC-5	GDSC1; GDSC2; CTRP2	4.42	4.9721	4.4192	9.9276
NCI-H446	GDSC1; GDSC2; CTRP2	4.4759	20.0985	-2.3291	30.0603
NCI-H2286	CTRP2	4.4945	35.9959	-10.2417	39.9807
NCI-H1048	GDSC1; GDSC2	4.554	18.4645	-5.7682	18.7499
NCI-H2347	GDSC1; GDSC2	4.7074	21.1883	-6.9739	21.8959
DMS 79	GDSC1; GDSC2; CTRP2	4.8309	14.6478	0.6938	21.977
NCI-H1688	GDSC1; GDSC2	4.8347	17.5334	-5.1391	16.2271
NCI-H2595	GDSC1; GDSC2	4.8453	17.3477	-5.0446	15.8851
NCI-H1838	GDSC1; GDSC2; CTRP2	5.1607	13.3789	1.617	18.3383
NCI-H2228	GDSC1; GDSC2; CTRP2	5.1633	20.6299	-1.995	28.0681
NCI-H226	GDSC1; GDSC2; CTRP2	5.3887	16.8308	0.0955	22.6006
NCI-H1435	GDSC1; GDSC2; CTRP2	6.0708	25.1772	-3.5001	29.2385
NCI-H2869	GDSC1; GDSC2	6.0983	24.595	-7.6615	21.3839
NCI-H661	GDSC1; GDSC2; CTRP2	6.1199	32.3752	-7.0581	33.9339
Lu-99	CTRP2	6.1486	20.3036	-0.9986	25.4796
NCI-H2444	GDSC1; GDSC2; CTRP2	6.474	27.3874	-4.2712	29.8204
HCC95	CTRP2	6.4755	18.4288	0.2077	21.6531
NCI-H322M	GDSC1; GDSC2	6.7259	24.9544	-7.4155	19.8723
NCI-H526	GDSC1; GDSC2; CTRP2	6.7733	28.9465	-4.8051	30.1502
RERF-LC-Ad1	CTRP2	7.144	7.9587	5.7779	0.1242
HARA [Human squamous cell lung carcinoma]	GDSC1; GDSC2; CTRP2	7.1573	22.9692	-1.5094	23.4954
NCI-H2122	GDSC1; GDSC2; CTRP2	7.1673	8.7876	5.4569	0.8889
HCC366	GDSC1; GDSC2; CTRP2	7.2028	24.0032	-1.9889	24.48
NCI-H2405	GDSC1; GDSC2; CTRP2	7.3645	24.9637	-2.3389	24.9524
SW1573	GDSC1; GDSC2; CTRP2	7.3788	24.048	-1.871	23.9419
MOR/CPR	CTRP2	7.3796	8.2503	5.7629	0.0893
PC-14	GDSC1; GDSC2; CTRP2	7.6656	28.7223	-3.9734	27.5046
LCLC-103H	GDSC1; GDSC2; CTRP2	7.7503	9.2661	5.5377	0.3413
NCI-H69	GDSC1; GDSC2; CTRP2	7.8852	22.6389	-0.7731	20.5596
NCI-H2291	GDSC1; GDSC2; CTRP2	8.0882	24.666	-1.6228	22.2794
NCI-H1650	GDSC1; GDSC2; CTRP2	8.1682	22.825	-0.6484	19.8046
NCI-H650	GDSC1; GDSC2; CTRP2	8.3927	23.161	-0.6443	19.4541
HCC2279	CTRP2	8.5372	33.9952	-5.9118	30.2485
NCI-H2023	GDSC1; GDSC2; CTRP2	8.5716	42.7446	-10.2445	33.7661
COLO 699	CTRP2	8.8627	39.8832	-8.5875	32.8463
HCC1171	CTRP2	9.007	28.4449	-2.7929	24.5441
NCI-H727	GDSC1; GDSC2; CTRP2	9.0672	37.1546	-7.0689	29.9548
NCI-H441	GDSC1; GDSC2; CTRP2	9.1848	24.3965	-0.6642	18.3508
SHP-77	GDSC1; GDSC2; CTRP2	9.1973	17.5414	2.6633	8.26
NCI-H2030	GDSC1; GDSC2; CTRP2	9.2694	35.7915	-6.2344	28.6451
HCC1833	CTRP2	9.3302	47.2085	-11.8675	35.0567
HCC827	GDSC1; GDSC2; CTRP2	9.3403	29.3389	-2.9832	23.317
NCI-H2085	GDSC1; GDSC2; CTRP2	9.5139	32.2005	-4.2668	25.3941
HCC15	GDSC1; GDSC2; CTRP2	9.5528	28.7049	-2.5115	22.0832
SK-LU-1	GDSC1; CTRP2	9.8848	41.4507	-8.5689	30.6584
HCC2108	CTRP2	10.6919	39.3528	-6.913	28.734
LXF 289	GDSC1; GDSC2; CTRP2	10.8736	30.1287	-2.249	19.8012
BEN	GDSC1; GDSC2; CTRP2	10.9122	45.7222	-9.8982	30.8564
NCI-H196	GDSC1; GDSC2; CTRP2	10.9412	32.0253	-3.1256	21.4994
A-549	GDSC1; GDSC2; CTRP2	11.2797	66.3955	-19.8869	37.0436
HCC1195	CTRP2	11.3027	49.8955	-11.6679	32.822
CAL-12T	GDSC1; GDSC2; CTRP2	11.347	48.5533	-10.9688	31.3893
NCI-H2126	CTRP2	11.792	25.4607	0.6061	12.407
RERF-LC-A1	CTRP2	11.8117	35.5997	-4.2461	23.4367
LOU-NH91	GDSC1; GDSC2; CTRP2	11.8534	42.5572	-7.626	27.3762
NCI-H2172	GDSC1; GDSC2; CTRP2	12.1061	29.1966	-0.9532	15.3567
NCI-H1299	GDSC1; GDSC2; CTRP2	12.139	24.4696	1.2793	9.3521
NCI-H1373	CTRP2	12.7043	33.9117	-2.8056	19.6664
NCI-H2009	GDSC1; GDSC2; CTRP2	12.7088	38.4048	-4.9744	22.6972
HCC1588	CTRP2	12.9981	34.5437	-2.9094	19.5322
HCC78	GDSC1; GDSC2; CTRP2	13.3717	35.6596	-3.1916	18.8099
NCI-H1792	GDSC1; GDSC2; CTRP2	13.7954	37.9056	-3.9812	19.831

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1; GDSC2	1.4666	9.3904	-3.5361	16.5258

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A2780	GDSC1; GDSC2; CTRP2	-6.1757	24.4887	-14.6339	56.9865
OV-90	GDSC1; GDSC2	-5.1702	15.176	-12.2339	50.0243
OVK18	GDSC1; GDSC2; CTRP2	-5.1439	58.3117	-29.913	52.5819
OV56	GDSC1; GDSC2	-2.3671	17.7688	-10.9267	42.6262
OAW42	GDSC1	-2.096	2.638	-4.6162	16.7067
TOV-21G	GDSC1; GDSC2	-1.9109	54.4455	-28.8311	46.8469
OC 314	GDSC1; GDSC2	-0.3571	21.3189	-10.9585	38.3118
JHOS-2	GDSC1; GDSC2	-0.2374	12.1744	-6.2861	30.6082
EFO-27	GDSC1; GDSC2	-0.0578	45.3762	-22.7363	43.8925
TOV-112D	GDSC1; GDSC2	0.0985	29.4733	-14.6546	40.4041
OVCAR-5	GDSC1; GDSC2	0.3061	17.2187	-8.3556	33.4981
SNU-840	CTRP2	0.9148	32.5221	-11.6796	45.9713
JHOS-4	GDSC1; GDSC2	1.65	10.4	-3.8972	17.7087
ES-2	GDSC1; GDSC2	1.6686	19.5361	-8.4147	30.7009
OVKATE	GDSC1; GDSC2	1.6957	13.0327	-5.1627	22.4612
EFO-21	GDSC1; GDSC2	2.0171	8.2942	-2.6103	10.7375
SNU-119	CTRP2	2.0414	14.7331	-1.9628	36.9375
OVCAR-3	GDSC1; GDSC2	2.367	4.4517	-0.696	0.7288
SNU-8	CTRP2	2.5795	23.0797	-5.509	39.8578
Caov-4	GDSC1; GDSC2	4.6213	18.7769	-5.8724	18.9549
OVISE	GDSC1; GDSC2; CTRP2	4.763	5.7086	4.7213	7.9598
Caov-3	GDSC2; CTRP2	5.5537	29.2373	-5.9635	33.8989
OAW28	GDSC1; GDSC2; CTRP2	5.7038	24.2378	-3.3377	29.591
Kuramochi	GDSC1; GDSC2; CTRP2	6.1579	20.1741	-0.9261	23.834
RMG-I	GDSC1; GDSC2; CTRP2	6.4074	28.1719	-4.7183	30.5935
IGROV-1	GDSC1; GDSC2; CTRP2	6.6351	35.5866	-8.2373	34.3902
ES2	CTRP2	7.1623	15.6185	2.1541	13.9326
DOV13	GDSC1; GDSC2; CTRP2	7.378	28.9446	-4.3142	28.4875
TYK-nu	GDSC1; GDSC2; CTRP2	7.6149	38.2729	-8.7805	33.6179
OVCAR-4	GDSC1; GDSC2; CTRP2	7.7477	30.3335	-4.7115	28.556
FU-OV-1	GDSC1; GDSC2; CTRP2	8.6176	26.5866	-2.169	22.688
ONCO-DG-1	CTRP2	10.3867	36.1417	-5.5565	27.2902
MCAS	CTRP2	10.4487	31.0546	-3.0071	22.9194
JHOC-5	CTRP2	11.9564	23.4782	1.6227	9.1606
OVTOKO	GDSC1; GDSC2; CTRP2	12.1793	33.9106	-3.1664	20.0935
OVCAR-8	GDSC1; GDSC2; CTRP2	13.6668	26.2693	1.3557	7.7006
OVSAHO	CTRP2	13.7198	39.0014	-4.5592	21.7608
HEY A8	CTRP2	14.2791	30.5985	-0.2381	11.9926
SK-OV-3	GDSC1; GDSC2; CTRP2	14.9484	43.0216	-5.6532	21.4389

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KP-1N	GDSC1; GDSC2	-0.5194	19.0747	-9.9736	37.5964
PL4	GDSC1; GDSC2	-0.0741	8.1609	-4.1424	23.2445
Panc 02.03	GDSC1; GDSC2	-0.0608	10.5359	-5.3187	27.4234
MIA PaCa-2	GDSC1; GDSC2	0.2027	17.5077	-8.5855	34.1086
Hs 766T	GDSC1; GDSC2	0.3266	36.7492	-18.1032	41.8627
Capan-2	GDSC1	0.4318	2.2759	-2.9193	0.3871
PaTu 8988t	GDSC1; GDSC2	0.8681	9.5542	-4.0743	20.3775
KP-2	GDSC1; GDSC2	1.8174	15.3853	-6.2355	25.4683
DAN-G	GDSC1; GDSC2	2.0043	26.9514	-11.844	34.9608
Panc 08.13	GDSC1; GDSC2	2.2485	10.2324	-3.3851	14.078
SW1990	GDSC1; GDSC2	2.4755	15.7236	-5.9062	23.1141
AsPC-1	GDSC1; GDSC2	2.6045	10.1298	-3.0933	11.9727
Panc 10.05	GDSC1; GDSC2	2.8493	19.4344	-7.4569	26.4095
MZ-PC-1	GDSC1; GDSC2	2.9814	4.9438	-0.6348	0.3019
PSN1	GDSC1; GDSC2	3.2435	16.5039	-5.7299	21.0303
PK-59	CTRP2	3.2832	33.1125	-9.8543	41.5594
HuP-T3	GDSC1; GDSC2	3.6458	13.6317	-4.0694	14.3183
SNU-410	CTRP2	3.7625	13.3749	0.3388	27.2368
Capan-1	GDSC1; GDSC2	4.4639	17.7839	-5.5032	18.0669
Panc 03.27	GDSC1; GDSC2	4.5435	15.6871	-4.4575	14.2682
PaTu 8902	GDSC1; GDSC2; CTRP2	4.7149	5.1949	4.7139	8.1263
Panc 04.03	GDSC1; GDSC2	5.0067	21.7479	-7.0371	21.5614
BxPC-3	GDSC1; GDSC2; CTRP2	5.4931	26.7511	-4.7718	32.1512
SU.86.86	GDSC1; GDSC2; CTRP2	5.623	30.8447	-6.7086	34.3027
SNU-213	CTRP2	6.3411	22.5529	-1.9639	27.2772
HuP-T4	GDSC1; GDSC2; CTRP2	7.4226	29.3821	-4.4967	28.7057
KP-4	GDSC1; GDSC2; CTRP2	7.7381	26.9289	-3.0221	25.7115
TCC-Pan2	CTRP2	8.3438	33.122	-5.6291	30.1461
Panc 05.04	CTRP2	9.7509	67.2199	-21.512	39.5134
QGP-1	GDSC1; GDSC2; CTRP2	9.7555	35.9322	-5.9306	27.6177
KP-3	GDSC1; GDSC2; CTRP2	10.5066	24.9197	0.0168	14.7837
SUIT-2	GDSC1; GDSC2; CTRP2	11.7232	24.3077	1.0998	10.3053
HPAF-II	GDSC1; CTRP2	11.932	36.329	-4.5158	22.8187
YAPC	GDSC1; GDSC2; CTRP2	12.7411	31.7663	-1.7549	16.5089
HPAC	GDSC1; GDSC2; CTRP2	13.0189	37.3042	-4.2239	21.0949
CFPAC-1	GDSC1; GDSC2; CTRP2	15.3007	36.4987	-2.3337	15.1173
L3.3	CTRP2	15.4559	32.6143	-0.4586	11.4029

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	GDSC1; GDSC2; CTRP2	-3.8427	12.5207	-7.0109	55.1894
NCI-H2452	GDSC1; GDSC2; CTRP2	-0.8705	11.2971	-3.3817	45.1427
MPP 89	GDSC1; GDSC2	1.1776	16.9344	-7.5069	29.9511
IST-Mes1	GDSC1; GDSC2	1.5692	13.2711	-5.3774	23.4647
NCI-H28	GDSC1; GDSC2; CTRP2	4.3423	22.0923	-3.4387	32.2419
ACC-MESO-1	CTRP2	9.5577	26.5848	-1.4653	20.8727
NCI-H2052	GDSC1; GDSC2; CTRP2	10.4327	38.5574	-6.7155	27.8444

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LNCaP clone FGC	GDSC1; GDSC2	-3.0363	6.8939	-6.2173	39.5187
PC-3	GDSC1; GDSC2	-0.1797	42.9963	-21.6481	43.7317
22Rv1	GDSC1; GDSC2; CTRP2	0.8049	29.8095	-10.4445	44.6173
NCI-H660	GDSC2	1.5602	3.6375	-0.742	1.6664
VCaP	GDSC1; GDSC2	1.6998	3.252	-0.5208	0.5909
DU145	GDSC1; GDSC2	1.7189	3.729	-0.7014	1.2598

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC1; GDSC2	1.2022	12.0399	-5.0497	23.2431
YD-15	CTRP2	14.5176	31.6645	-0.5822	12.6211

Cancer Drug Sensitivity Data Curated from 63 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MZ-MEL-2	GDSC1; GDSC2	-4.6308	49.4699	-28.6926	49.4637
A2058	GDSC1; GDSC2	-3.7327	8.5785	-7.6925	44.0688
IGR-37	GDSC1; GDSC2	-2.8297	11.4826	-8.2418	41.5703
MeWo	GDSC1; GDSC2	-2.7332	8.0136	-6.463	38.8029
M14	GDSC1	-0.8417	7.4802	-6.0507	20.7385
WM35	GDSC1; GDSC2	-0.7213	16.2685	-8.7429	36.4879
WT2-iPS	GDSC1; GDSC2	-0.7031	14.4603	-7.8241	35.0166
G-mel	GDSC1; GDSC2	-0.538	24.3564	-12.6294	40.1022
CHL-1	GDSC1; GDSC2	-0.4864	68.459	-34.6357	46.2909
A101D	GDSC1; GDSC2	-0.2709	46.0783	-23.2653	44.2585
IST-MEL1	GDSC1; GDSC2	-0.1383	40.0568	-20.1437	43.2229
Hs 938.T	GDSC1; GDSC2	0.227	48.0145	-23.8184	43.8665
HT-144	GDSC1; GDSC2	0.2351	9.0144	-4.3128	23.0471
SK-MEL-2	GDSC1; GDSC2	0.3	14.3249	-6.914	30.7034
Hs 940.T	GDSC1; GDSC2	0.571	20.514	-9.7851	35.0797
451Lu	GDSC1; GDSC2	0.7574	15.965	-7.3604	30.5872
A-431	GDSC1; GDSC2	0.8899	14.4568	-6.5008	28.2906
COLO 800	GDSC1; GDSC2	1.0061	10.6442	-4.5087	21.7654
VMRC-MELG	GDSC1; GDSC2	1.1522	10.7581	-4.4516	21.1801
IGR-1	GDSC1; GDSC2	1.1654	3.2271	-0.7769	2.3063
WM115	GDSC1; GDSC2	1.3507	27.6145	-12.6985	36.8968
UACC-257	GDSC1; GDSC2	1.3754	6.6602	-2.2651	10.2494
UACC-62	GDSC1; GDSC2	1.3755	15.8506	-6.8101	27.9367
RVH-421	GDSC1; GDSC2	1.386	17.9276	-7.8365	30.1774
LB373-MEL-D	GDSC1; GDSC2	1.448	13.7235	-5.6955	24.7431
WM1552C	GDSC1; GDSC2	1.4486	17.6414	-7.6444	29.6522
WM278	GDSC1; GDSC2	1.4595	18.6173	-8.122	30.5811
GAK	GDSC1; GDSC2	1.5516	10.7192	-4.1278	18.9148
MZ-MEL-7	GDSC1; GDSC2	1.6149	3.2048	-0.5394	0.7148
COLO 783	GDSC1; GDSC2	1.6525	9.3086	-3.3593	15.2655
LB2518-MEL	GDSC1; GDSC2	1.752	7.9364	-2.6199	11.3427
CP66-MEL	GDSC1; GDSC2	1.87	11.8872	-4.4663	19.5339
MMAc-SF	GDSC1; GDSC2	1.9434	6.6933	-1.8989	7.0796
SH-4	GDSC1; GDSC2	2.1159	17.4119	-7.0116	26.8292
Mel Ho	GDSC1; GDSC2; CTRP2	2.3366	46.6609	-17.4308	44.55
COLO 792	GDSC1; GDSC2	2.35	15.094	-5.6893	22.7201
COLO 829	GDSC1; GDSC2	2.7122	13.4168	-4.6045	18.2396
CP50-MEL-B	GDSC1; GDSC2	2.8633	18.0055	-6.7422	24.6471
A-388	GDSC1; GDSC2	2.9	24.298	-9.8249	30.7925
SK-MEL-3	GDSC1; GDSC2	3.1747	14.6392	-4.8724	18.2958
RPMI-7951	GDSC1; GDSC2; CTRP2	3.3365	34.5685	-10.5327	40.733
SK-MEL-24	GDSC1; GDSC2	3.4679	20.5967	-7.5706	25.5132
COLO 679	GDSC1; GDSC2	3.5552	13.763	-4.1918	14.9788
HMV-II	GDSC1; GDSC2	4.14	16.7546	-5.2288	17.7302
SK-MEL-5	GDSC1; GDSC2; CTRP2	4.558	6.1162	4.402	9.5848
SK-MEL-1	GDSC1; GDSC2; CTRP2	4.5723	21.8996	-3.1411	31.3182
COLO 741	CTRP2	4.7932	5.7574	4.7452	8.5002
DJM-1	GDSC1; GDSC2	5.0114	18.2378	-5.357	16.6644
Hs 852.T	CTRP2	5.2734	51.0647	-17.1114	42.0747
SK-MEL-31	GDSC1; GDSC2; CTRP2	8.1044	22.6779	-0.6241	19.8401
WM793	GDSC1; GDSC2; CTRP2	8.2849	49.2063	-13.699	36.5616
Hs 944.T	CTRP2	9.2933	29.2194	-2.9594	24.4472
SK-MEL-28	GDSC1; GDSC2; CTRP2	10.2622	26.1979	-0.7704	17.1575
LOX-IMVI	GDSC1; GDSC2; CTRP2	10.6256	49.3138	-11.901	32.901
Mel JuSo	GDSC1; GDSC2; CTRP2	10.7182	23.1371	1.0088	11.7056
WM1799	CTRP2	11.5421	50.0755	-11.5741	32.5021
G-361	GDSC1; GDSC2; CTRP2	11.6042	42.8896	-7.9749	28.0658
IPC-298	GDSC1; GDSC2; CTRP2	12.2399	49.8129	-10.9155	30.4494
A-375	GDSC1; GDSC2; CTRP2	12.3078	26.8705	0.2734	11.9861
Hs 936.T	CTRP2	12.351	26.2737	0.5777	11.8423
MDA-MB-435S	CTRP2	13.2275	33.1565	-2.0941	17.5586
SK-MEL-30	GDSC1; GDSC2; CTRP2	14.1682	30.6201	-0.3145	11.6131
EquiPSC Line K2	GDSC1; GDSC2	3.1706	26.2843	-10.6024	31.4917

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1; GDSC2	-7.544	29.2597	-21.3105	53.5231

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-LMS-1	GDSC1; GDSC2	-7.2379	1.6862	-8.4161	61.1363
Hs 633.T	GDSC1; GDSC2	-6.1222	4.2573	-8.1841	54.6231
G-402	GDSC1; GDSC2	-5.5566	32.9055	-21.2855	50.5609
HT-1080	GDSC1; GDSC2	-4.8249	43.3876	-25.8352	49.6189
SW872	GDSC1; GDSC2	-3.4708	10.5705	-8.3977	43.7565
MES-SA	GDSC1; GDSC2	-2.7531	8.1436	-6.5446	39.0168
SK-UT-1	GDSC1; GDSC2	-1.8392	18.8888	-11.0178	41.4919
VA-ES-BJ	GDSC1; GDSC2	-0.8897	60.3198	-30.9045	46.1852
MFH-ino	GDSC1; GDSC2	-0.559	180.2117	-90.5721	48.6024
KYM-1	GDSC1; GDSC2	-0.5011	27.3836	-14.1115	41.0412
G-401	GDSC1; GDSC2	-0.2699	22.5612	-11.5063	38.6648
SW982	GDSC1; GDSC2	0.022	32.4551	-16.2092	41.3957
GCT	GDSC1; GDSC2	0.3229	16.5574	-8.0112	32.8588
A-204	GDSC1; GDSC2	0.6508	33.5672	-16.2444	40.5114
STS-0421	GDSC1; GDSC2	0.9513	15.0646	-6.7549	28.7721
TE 441.T	GDSC2	1.2684	7.5766	-2.7902	13.733
EW-8	GDSC1; GDSC2	1.4317	6.1435	-1.976	8.5155
SW684	GDSC1; GDSC2	2.3108	11.4425	-3.9286	16.3697
Rh30	GDSC1; GDSC2	2.8541	14.7905	-5.1727	19.9906
Rh41	GDSC1; GDSC2; CTRP2	2.9213	19.5031	-3.437	35.1279
RD	GDSC1; GDSC2	6.136	23.4803	-7.1045	19.9612
Rh18	GDSC1; CTRP2	6.3079	26.159	-3.7941	29.3324
RKN	GDSC1; GDSC2; CTRP2	10.5329	26.6123	-0.7817	16.8365

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HGC-27	GDSC1; GDSC2	-7.2855	3.9471	-9.293	59.4821
TMK-1	GDSC1; GDSC2	-0.7129	21.6871	-11.4432	39.4756
ECC10	GDSC1; GDSC2; CTRP2	-0.4853	6.1301	-1.1052	41.2
SK-GT-2	GDSC1; GDSC2	0.1443	18.8007	-9.2804	35.2789
RF-48	GDSC1; GDSC2	0.2052	29.7455	-14.7021	40.2666
SNU-16	GDSC1; GDSC2	0.3592	10.3744	-4.891	24.8549
SCH	GDSC1; GDSC2	0.4474	15.9553	-7.608	31.8101
23132/87	GDSC1; GDSC2; CTRP2	0.6847	15.2772	-3.5513	40.638
SNU-1	GDSC1; GDSC2	0.7361	21.4861	-10.1359	35.2104
SNU-5	GDSC1; GDSC2	0.8521	14.5913	-6.5983	28.6237
GCIY	GDSC1; GDSC2	1.3687	8.4483	-3.1448	14.8875
HSC-39	GDSC1; GDSC2	1.4315	9.5224	-3.6272	17.0266
KATO III	GDSC1; GDSC2	1.6971	8.5509	-2.9569	13.1966
Hs 746.T	GDSC1; GDSC2	1.8726	15.5657	-6.2827	25.477
MKN28	GDSC1; GDSC2	1.8823	8.4219	-2.7642	11.813
RERF-GC-1B	GDSC1; GDSC2	2.1935	8.0001	-2.353	9.0415
IM95	GDSC1; GDSC2	2.2137	4.3416	-0.7193	0.9087
OCUM-1	GDSC1; GDSC2	2.3498	16.9563	-6.6084	25.3341
NCI-N87	GDSC1; CTRP2	2.7128	33.297	-10.4491	41.6069
TGBC11TKB	GDSC1; GDSC2	3.6609	15.3769	-4.8928	17.4371
MKN1	GDSC1; GDSC2; CTRP2	3.7427	14.4719	-0.2134	26.9044
MKN7	GDSC1; GDSC2	4.2911	22.5886	-7.9485	24.9147
GSS	CTRP2	5.1928	22.8158	-3.0611	31.5085
Fu97	GDSC1; GDSC2; CTRP2	5.5562	32.3614	-7.5231	35.2336
GSU	CTRP2	6.7256	7.3756	5.8249	0.1879
ECC12	GDSC2; CTRP2	7.0209	19.0268	0.348	19.2524
MKN45	GDSC1; GDSC2; CTRP2	7.2574	8.6952	5.5415	0.582
MKN74	CTRP2	9.0944	28.8844	-2.9441	24.709
SNU-620	CTRP2	9.2612	31.0754	-3.9018	26.2085
NUGC-3	GDSC1; GDSC2; CTRP2	9.5068	58.4764	-17.345	37.3587
NUGC-4	GDSC1; GDSC2; CTRP2	10.8329	41.9366	-8.084	29.0459
SNU-719	CTRP2	11.2553	27.468	-0.6975	16.6444
KE-39	CTRP2	12.6477	36.4351	-4.0617	22.1151
SNU-668	CTRP2	13.257	48.5776	-9.5516	28.899
AGS	GDSC1; GDSC2; CTRP2	15.9295	37.2933	-2.3119	14.4815
SNU-1077	CTRP2	11.5403	24.4999	0.8959	11.8523
SNG-M	GDSC1; GDSC2; CTRP2	13.0338	28.7584	-0.1508	12.3337

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
K5	GDSC1; GDSC2	-0.896	150.7904	-76.1432	48.4567
KMH-2	GDSC1; GDSC2	-0.3539	11.2293	-5.9122	29.9643
HTC-C3	GDSC1; GDSC2	0.1126	11.9541	-5.8835	28.6122
IHH-4	GDSC1; GDSC2	0.4302	29.144	-14.2151	39.5931
FTC-133	GDSC1; GDSC2	0.7776	26.6268	-12.6711	37.8245
ML-1 [Human leukemia]	GDSC1; GDSC2; CTRP2	0.9477	22.3257	-6.6548	42.5586
ASH-3	GDSC1; GDSC2	1.8834	20.45	-8.7009	30.7903
TT2609-C02	GDSC1; GDSC2	2.1044	13.0355	-4.8579	20.4739
WRO	GDSC1; GDSC2	2.1803	25.2814	-10.8728	33.513
8305C	GDSC1; GDSC2; CTRP2	3.2324	28.8439	-7.776	39.1017
CGTH-W-1	GDSC1; GDSC2; CTRP2	6.54	28.704	-4.8751	30.6112
CAL-62	GDSC1; GDSC2; CTRP2	7.7149	38.8316	-8.9787	33.6767
8505C	GDSC1; GDSC2; CTRP2	9.5135	39.4363	-7.8559	30.3201
B-CPAP	GDSC1; GDSC2; CTRP2	10.9101	33.3872	-3.8145	22.822
TT	GDSC1; GDSC2; CTRP2	12.9018	36.7519	-4.0382	20.8964
BHT-101	GDSC1; GDSC2; CTRP2	13.5174	31.6	-1.1718	14.3362

Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
BICR 10	GDSC1	-3.8332	35.8516	-22.6822	46.5745
JHU-011	GDSC1; GDSC2	-1.0268	126.6855	-64.2005	48.2238
BICR 22	GDSC1; GDSC2	-1.0075	52.2528	-26.9706	45.7426
HO-1-N-1	GDSC1; GDSC2	-0.97	41.5874	-21.6074	44.6428
CAL-33	GDSC1; GDSC2	-0.9152	28.5715	-15.0554	42.2488
HO-1-u-1	GDSC1; GDSC2	-0.7467	33.3605	-17.3065	43.0013
HSC-2	GDSC1; GDSC2	-0.6219	36.5727	-18.8072	43.3866
KON	GDSC1; GDSC2	-0.4501	69.8073	-35.2794	46.3314
BB49-HNC	GDSC1	-0.3654	16.3678	-10.0905	31.7463
PCI-04B	GDSC1; GDSC2	-0.3197	29.6277	-15.0811	41.3125
JHU-029	GDSC1; GDSC2	-0.2043	32.8659	-16.6035	41.9175
PCI-38	GDSC1	0.18	19.8867	-11.4162	32.8795
CAL-27	GDSC1; GDSC2	0.2654	12.3385	-5.9495	28.3921
DOK	GDSC1; GDSC2	0.3162	28.9605	-14.2176	39.776
PCI-30	GDSC1; GDSC2	0.5717	57.247	-28.1485	44.4847
JHU-022	GDSC1; GDSC2	0.7824	30.2134	-14.4597	39.2124
SAT [Human HNSCC]	GDSC1; GDSC2	0.8331	21.6552	-10.1414	35.0283
OSC-19	GDSC1; GDSC2	0.87	3.4134	-1.0475	4.3323
KOSC-2	GDSC1; GDSC2	0.9042	25.5429	-12.026	37.0112
PE/CA-PJ15	GDSC1; GDSC2	1.0929	18.7579	-8.4845	32.0092
PCI-15A	GDSC1; GDSC2	1.1093	9.4647	-3.8427	18.7739
NCI-H3118	GDSC1; GDSC2	1.1469	10.7928	-4.4729	21.2757
BICR 78	GDSC1; GDSC2	1.2584	18.0915	-8.0196	30.8076
SCC-15	GDSC1; GDSC2	1.3847	23.3356	-10.5349	34.4914
UPCI-SCC-090	GDSC1; GDSC2	1.3878	6.3541	-2.108	9.3489
SCC-9	GDSC1; GDSC2	1.4324	5.063	-1.4604	5.603
Ca9-22	GDSC1; GDSC2	1.452	10.6659	-4.1765	19.3518
BB30-HNC	GDSC1; GDSC2	1.6761	26.0023	-11.6321	35.2762
BICR 31	GDSC2	1.7502	5.0778	-1.2711	4.1532
SCC-4	GDSC1; GDSC2	1.8605	16.996	-7.0017	27.3414
SKN-3	GDSC1; GDSC2	1.9593	10.7802	-3.8572	16.831
SNU-1076	CTRP2	2.6751	15.9986	-1.9592	35.2364
OSC-20	GDSC1; GDSC2	2.6936	11.5289	-3.7034	14.5993
PCI-06A	GDSC1; GDSC2	3.0807	14.9981	-5.1125	19.3284
BHY	GDSC1; GDSC2; CTRP2	3.2689	19.7046	-3.2173	34.0586
SAS	GDSC1; GDSC2	3.6946	17.171	-5.7354	20.1883
FaDu	GDSC1; GDSC2	3.8572	12.4939	-3.3998	11.1029
SCC-25	GDSC1; GDSC2; CTRP2	4.0954	29.0809	-7.1358	37.1396
LB771-HNC	GDSC1; GDSC2	4.2027	28.6848	-11.0083	30.4397
Detroit 562	GDSC1; GDSC2; CTRP2	4.3104	28.2908	-6.555	36.2308
YD-10B	CTRP2	5.8603	42.6292	-12.4017	39.403
HSC-4	GDSC1; GDSC2; CTRP2	7.2286	27.5318	-3.729	27.7581
SNU-1214	CTRP2	7.2412	20.9687	-0.4453	22.0555
YD-8	CTRP2	8.0258	36.7781	-7.704	33.038
SNU-46	CTRP2	11.6025	31.5356	-2.4189	20.2131
SNU-1066	CTRP2	11.8341	32.9536	-2.9439	20.9987
HSC-3	GDSC1; GDSC2; CTRP2	12.438	26.4978	0.5277	11.157
SNU-1041	CTRP2	13.207	35.198	-3.0817	19.6342
SNU-899	CTRP2	14.1584	36.0258	-2.8433	18.0981

Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
T24	GDSC1; GDSC2	-8.4246	357.2133	-185.6748	50.4902
SW780	GDSC1; GDSC2	-0.1867	33.6532	-16.9824	42.0672
647V	GDSC1; GDSC2	0.3071	16.5874	-8.0392	32.9457
J82	GDSC1; GDSC2	0.7593	16.7568	-7.7543	31.3834
HT-1197	GDSC1; GDSC2	0.9178	23.4876	-10.9879	35.8939
CAL-29	GDSC1; GDSC2; CTRP2	1.0911	31.5428	-11.0363	44.3608
JMSU-1	CTRP2	1.5224	15.5645	-2.8615	39.6451
253J	CTRP2	1.9701	12.8487	-1.1508	35.7142
BFTC-905	GDSC1; GDSC2; CTRP2	4.2023	5.0171	4.1972	11.2711
TCCSUP	GDSC1; GDSC2; CTRP2	4.489	36.2593	-10.378	39.0143
5637	GDSC1; GDSC2; CTRP2	4.6512	24.2129	-4.2255	32.8473
HT-1376	GDSC1; GDSC2; CTRP2	6.4787	17.9371	0.456	19.5408
253J-BV	CTRP2	6.9385	22.8127	-1.6068	25.4251
639V	GDSC1; GDSC2; CTRP2	7.3692	8.4929	5.6711	0.226
VM-CUB-1	CTRP2	7.4512	25.7444	-2.6592	26.7293
RT-4	GDSC1; GDSC2; CTRP2	7.5659	32.1597	-5.768	30.3158
UM-UC-3	GDSC1; GDSC2; CTRP2	9.9828	32.9082	-4.2632	24.7743
SW1710	GDSC1; GDSC2; CTRP2	10.7031	29.9427	-2.2799	20.0826
KU-19-19	GDSC1; GDSC2; CTRP2	13.2808	44.1642	-7.373	25.5479
RT-112	GDSC1; GDSC2; CTRP2	15.1523	43.1616	-5.5821	21.1297

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PA-1	GDSC1; GDSC2	-5.1737	33.0708	-21.0229	50.0181
C-33 A	GDSC1; GDSC2	-1.2262	11.8501	-6.9756	34.8919
CAL-39	GDSC1; GDSC2	-0.5164	18.3743	-9.621	37.1707
SW962	GDSC1; GDSC2	-0.4795	59.7191	-30.2601	45.751
NT2-D1	GDSC1; GDSC2	-0.3758	31.6503	-16.1394	41.9473
BPH-1	GDSC1; GDSC2	-0.219	15.5381	-7.9523	34.0331
SKN	GDSC1; GDSC2	-0.1973	52.2457	-26.2874	44.8394
OVCA433	GDSC1; GDSC2	0.1812	25.032	-12.3653	38.5932
ME-180	GDSC1; GDSC2	0.3187	23.4525	-11.4618	37.508
Ca Ski	GDSC1; GDSC2	0.3252	17.3479	-8.4045	33.5373
HEY	GDSC1; GDSC2	0.5249	18.2995	-8.7161	33.6084
SiSo	GDSC1; GDSC2	0.6877	10.3955	-4.6363	23.0646
KGN	GDSC1; GDSC2	0.7427	15.8645	-7.3221	30.5399
OMC-1 [Human cervical carcinoma]	GDSC1; GDSC2	0.7913	12.7669	-5.7366	26.4454
OV17R	GDSC1; GDSC2	0.8527	9.9436	-4.2802	21.2607
DSH1	GDSC1; GDSC2	0.8702	11.628	-5.1056	24.257
OVMIU	GDSC1; GDSC2	1.2551	6.1845	-2.119	9.7009
NEC8	GDSC1; GDSC2	1.2677	4.7889	-1.4382	5.7936
JHOS-3	GDSC1; GDSC2	1.4181	9.5228	-3.6374	17.105
ACC-OV7	GDSC1; GDSC2	1.6046	22.9258	-10.1547	33.5855
JEG-3	GDSC1; GDSC2	1.6185	3.1491	-0.5162	0.6306
TC-YIK	GDSC1; GDSC2	1.645	9.8967	-3.6533	16.6434
OVCA420	GDSC1; GDSC2	1.6539	8.194	-2.8138	12.5641
C-4-I	GDSC1; GDSC2	1.8053	14.2838	-5.6988	23.9377
SW756	GDSC1; GDSC2	1.8809	10.487	-3.7705	16.6278
SW954	GDSC1; GDSC2	1.9004	14.3778	-5.6731	23.6465
SiHa	GDSC1; GDSC2	1.9323	15.2621	-6.0866	24.7995
HEC-1	GDSC1; GDSC2	1.9476	3.5231	-0.5203	0.4448
NCC-IT	GDSC2	2.0125	10.0238	-3.4498	15.2948
HT-3	GDSC1; GDSC2	2.0558	7.9155	-2.4034	9.5757
JAR	GDSC1; GDSC2	2.1404	3.91	-0.586	0.5287
LB831-BLC	GDSC1; GDSC2	2.3074	13.2544	-4.8164	19.8802
DoTc2 4510	GDSC1; GDSC2	2.4799	4.178	-0.5511	0.2965
PWR-1E	GDSC1; GDSC2	2.6403	16.8715	-6.3492	24.044
UWB1.289	GDSC1; GDSC2	2.6846	19.2581	-7.4936	26.8104
PEO1	GDSC1; GDSC2	2.8175	15.2801	-5.4381	20.9503
SKG-IIIa	GDSC1; GDSC2	2.903	15.7018	-5.5827	21.2422
MS751	GDSC1; GDSC2	3.572	14.7652	-4.6596	16.7531
HeLa	GDSC1; GDSC2; CTRP2	7.1374	8.3092	5.6414	0.3948

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Temsirolimus (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Temsirolimus caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[8]
Metreleptin	DM1NOEK	Moderate	Decreased metabolism of Temsirolimus caused by Metreleptin mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[9]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Temsirolimus caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[8]
Arn-509	DMT81LZ	Major	Increased metabolism of Temsirolimus caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[8]
Oliceridine	DM6MDCF	Moderate	Increased plasma concentrations of Temsirolimus and Oliceridine due to competitive inhibition of the same metabolic pathway.	Acute pain [MG31]	[10]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Temsirolimus and Inotersen.	Amyloidosis [5D00]	[11]
Siltuximab	DMGEATB	Moderate	Additive myelosuppressive effects by the combination of Temsirolimus and Siltuximab.	Anemia [3A00-3A9Z]	[11]
Troleandomycin	DMUZNIG	Major	Increased metabolism of Temsirolimus caused by Troleandomycin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[8]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Temsirolimus caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[12]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Temsirolimus caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[8]
Tucatinib	DMBESUA	Major	Increased metabolism of Temsirolimus caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[8]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Temsirolimus caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Cabazitaxel	DMPAZHC	Moderate	Increased plasma concentrations of Temsirolimus and Cabazitaxel due to competitive inhibition of the same metabolic pathway.	Breast cancer [2C60-2C6Y]	[10]
Levonorgestrel	DM1DP7T	Moderate	Increased plasma concentrations of Temsirolimus and Levonorgestrel due to competitive inhibition of the same metabolic pathway.	Contraceptive management [QA21]	[10]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Temsirolimus caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[8]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Temsirolimus caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[13]
OPC-34712	DMHG57U	Moderate	Increased plasma concentrations of Temsirolimus and OPC-34712 due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[10]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Temsirolimus caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[13]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Temsirolimus caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[8]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Temsirolimus caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[8]
Boceprevir	DMBSHMF	Major	Increased metabolism of Temsirolimus caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[8]
177Lu-DOTATATE	DMT8GVU	Major	Increased risk of nephrotoxicity by the combination of Temsirolimus and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[10]
Cobicistat	DM6L4H2	Major	Increased metabolism of Temsirolimus caused by Cobicistat mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Temsirolimus caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[8]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Temsirolimus and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[14]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Temsirolimus caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[13]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Temsirolimus caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[8]
Givosiran	DM5PFIJ	Major	Increased risk of nephrotoxicity by the combination of Temsirolimus and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[10]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Temsirolimus caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[15]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Temsirolimus caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[13]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Temsirolimus caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[13]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Temsirolimus caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[11]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Temsirolimus and Denosumab.	Low bone mass disorder [FB83]	[16]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Temsirolimus caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Temsirolimus caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[8]
Ceritinib	DMB920Z	Major	Increased metabolism of Temsirolimus caused by Ceritinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[8]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Temsirolimus caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[8]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Temsirolimus caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[11]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Temsirolimus caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
Idelalisib	DM602WT	Major	Increased metabolism of Temsirolimus caused by Idelalisib mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[8]
Moxetumomab pasudotox	DMN63DZ	Major	Increased risk of nephrotoxicity by the combination of Temsirolimus and Moxetumomab pasudotox.	Mature B-cell leukaemia [2A82]	[10]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Temsirolimus caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Temsirolimus caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[17]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Temsirolimus caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[8]
LGX818	DMNQXV8	Moderate	Increased metabolism of Temsirolimus caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[18]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Temsirolimus caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[8]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Temsirolimus and Tecfidera.	Multiple sclerosis [8A40]	[19]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Temsirolimus and Siponimod.	Multiple sclerosis [8A40]	[8]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Temsirolimus and Fingolimod.	Multiple sclerosis [8A40]	[20]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Temsirolimus and Ocrelizumab.	Multiple sclerosis [8A40]	[21]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Temsirolimus and Ozanimod.	Multiple sclerosis [8A40]	[11]
Deflazacort	DMV0RNS	Moderate	Increased plasma concentrations of Temsirolimus and Deflazacort due to competitive inhibition of the same metabolic pathway.	Muscular dystrophy [8C70]	[10]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Temsirolimus caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Temsirolimus caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[13]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Temsirolimus caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[13]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Temsirolimus caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[22]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Temsirolimus caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[23]
Lonafarnib	DMGM2Z6	Major	Increased metabolism of Temsirolimus caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[8]
Enzalutamide	DMGL19D	Major	Increased metabolism of Temsirolimus caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[8]
Tildrakizumab	DMLW9HG	Moderate	Additive immunosuppressive effects by the combination of Temsirolimus and Tildrakizumab.	Psoriasis [EA90]	[11]
Risankizumab	DMM32GT	Moderate	Additive myelosuppressive effects by the combination of Temsirolimus and Risankizumab.	Psoriasis [EA90]	[11]
Ixekizumab	DMXW92T	Moderate	Additive myelosuppressive effects by the combination of Temsirolimus and Ixekizumab.	Psoriasis [EA90]	[11]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Temsirolimus and Rilonacept.	Rheumatoid arthritis [FA20]	[11]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Temsirolimus and Golimumab.	Rheumatoid arthritis [FA20]	[24]
Sarilumab	DMOGNXY	Moderate	Additive myelosuppressive effects by the combination of Temsirolimus and Sarilumab.	Rheumatoid arthritis [FA20]	[11]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Temsirolimus when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[25]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Temsirolimus caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[13]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Temsirolimus caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[11]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Temsirolimus caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Armodafinil	DMGB035	Minor	Increased metabolism of Temsirolimus caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
LEE011	DMMX75K	Moderate	Decreased metabolism of Temsirolimus caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Telavancin	DM58VQX	Major	Increased risk of nephrotoxicity by the combination of Temsirolimus and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[10]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Temsirolimus caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[27]
Plazomicin	DMKMBES	Major	Increased risk of nephrotoxicity by the combination of Temsirolimus and Plazomicin.	Urinary tract infection [GC08]	[10]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Temsirolimus caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[8]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
DL-alpha-tocopherol	E00052	2116	Antioxidant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Temsirolimus 25mg/ml solution	25mg/ml	Solution	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5892).
• [2] BDDCS applied to over 900 drugs
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [6] Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659.
• [7] Drug Interactions Flockhart Table
• [8] Cerner Multum, Inc. "Australian Product Information.".
• [9] Product Information. Myalept (metreleptin). Bristol-Myers Squibb, Princeton, NJ.
• [10] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [11] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [12] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [13] Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [14] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [15] Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [16] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [17] Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
• [18] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [19] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [20] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [21] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [22] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [23] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [24] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [25] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [26] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [27] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.